Introduction

Polycythemia vera is a clonal disorder arising in a multipotent hematopoietic progenitor cell that causes the accumulation of morphologically normal red cells, white cells, platelets, and their progenitors in the absence of a definable stimulus and to the exclusion of nonclonal hematopoiesis.1,2 First described in 1892,3 polycythemia vera is not a new disease and while uncommon, with an incidence of at least 2 per 100 000,4-6 it is not a rare disease. Yet, after 10 decades of careful clinical and laboratory investigation, the etiology of polycythemia vera remains unknown and there is no consensus as to the optimal therapy for the disorder.7 There is, however, no reason for this to be so. Although the molecular basis of polycythemia vera remains elusive, it is the central thesis of this review that the pathophysiology of polycythemia vera is sufficiently well defined for the provision of a rational treatment program that prolongs life, alleviates the specific morbidities associated with the disease, and avoids complications related to the consequences of the underlying molecular defect. However, for such an approach to be successful, it is first necessary to recognize the contradictions between what is actually known about this disease and how that knowledge has been interpreted and applied clinically, and that is the purpose of this review.

The pathogenesis of polycythemia vera: polycythemia vera is a myeloaccumulative disorder not a myeloproliferative disorder

Erythropoiesis and growth factor hypersensitivity

Because it involves a multipotent hematopoietic progenitor cell, the hallmark of polycythemia vera is trilineage hematopoietic cell hyperplasia. However, erythrocytosis is its most prominent clinical manifestation, the cause of its most serious complications, and the “sine qua non” for its diagnosis. Therefore, most investigations of the pathogenesis of polycythemia vera have focused on erythropoiesis but with paradoxical results. Red cell life span is not prolonged in polycythemia vera8 and the erythroid progenitor cell pool is not expanded at the expense of the myeloid progenitor cell pool.9 At the same time, neither hyperoxia10nor renal failure11 suppress erythropoiesis in polycythemia vera patients, phlebotomy does not stimulate it,12,13 and serum erythropoietin levels are lower than in any other disease14 (Figure1).

Fig. 1.

Relationship between serum erythropoietin and hemoglobin in patients with polycythemia vera (○), secondary erythrocytosis (●) or relative erythrocytosis (x).

Adapted from Handin et al369 with permission of the publisher, Lippincott, Williams, and Wilkins.

Fig. 1.

Relationship between serum erythropoietin and hemoglobin in patients with polycythemia vera (○), secondary erythrocytosis (●) or relative erythrocytosis (x).

Adapted from Handin et al369 with permission of the publisher, Lippincott, Williams, and Wilkins.

These paradoxical results are due to the ability of polycythemia vera erythroid progenitor cells to proliferate in vitro in the absence of erythropoietin.15 This unusual behavior, however, does not define the limits of the abnormal clone since not all polycythemia vera erythroid progenitor cells exhibit erythropoietin-independence in vitro.16,17 Importantly, primitive polycythemia vera erythroid progenitor cells exhibiting either erythropoietin-dependence or -independence could give rise to both erythropoietin-dependent and -independent progeny, a characteristic that appeared fixed given that it remained constant over time when these progenitor cells were cultured in vitro. It is also worth noting that the in vitro proliferation of polycythemia vera erythroid progenitor cells in the absence of erythropoietin was not robust.17 This may be a consequence of the tendency of these cells to differentiate faster in vitro than normal erythroid progenitor cells in the absence of erythropoietin.18 Thus, the dominance exerted by the polycythemia vera erythroid clone over polyclonal erythroid precursors2 could be due in part to its ability to complete its differentiation more efficiently in a low erythropoietin milieu.

This dominance may also involve transforming growth factors produced by polycythemia vera mononuclear cells19 and the hypersensitivity of polycythemia erythroid progenitor cells to interleukin 3 (IL-3), granulocyte macrophage–colony-stimulating factor (GM-CSF),20 stem cell factor (SCF),21 and insulinlike growth factor (IGF-1).22 Despite claims to the contrary,23,24 this hypersensitivity does not appear to be the consequence of an abnormality in the negative regulatory hematopoietic phosphatase, SHP-1.25,26Indeed, evidence has been obtained for increased activity of a membrane-associated protein tyrosine phosphatase in polycythemia vera erythroid progenitor cells27 and although overexpression of INK4a and ARF has also been documented in these cells28 and constitutive phosphorylation of STAT3 has been observed in the granulocytes in a minority of patients,29no consistent abnormality of signal transduction or cell cycle regulation has been identified to date in polycythemia vera nor have mutations been identified in p53 or Ras during the chronic phase of the illness.30 There is evidence for both gain31,32 and loss33,34 of suppressor genes in polycythemia vera but exactly which genes and how they might affect erythroid progenitor cell behavior remain unknown.

Erythropoietin receptor function

Given the ability of polycythemia vera erythroid progenitor cells to survive in vitro in the absence of erythropoietin as well as their hypersensitivity to erythropoietin in particular and hematopoietic growth factors in general, there has been substantial interest in growth factor receptor function in this disease. c-Kit expression, ligand affinity, and internalization were normal in polycythemia vera erythroid progenitor cells35 but the development of erythropoietin hypersensitivity or independence as a consequence of gain in function mutations in the ligand-binding and cytoplasmic domains of the erythropoietin receptor36 raised the possibility that this receptor was involved in the pathogenesis of the disease. However, erythropoietin receptor expression and ligand binding were not different in polycythemia vera erythroid progenitor cells compared with normal erythroid progenitor cells.37,38Furthermore, no erythropoietin receptor gene amplification, rearrangements, or functional mutations have been identified in polycythemia vera patients.39 This is not surprising because forced expression of the erythropoietin receptor in primitive hematopoietic stem cells did not induce autonomous proliferation, enhance progenitor cell renewal, or stimulate granulopoiesis,40 all of which are features of polycythemia vera. Furthermore, although expression of a constitutively-active erythropoietin receptor caused both erythrocytosis and thrombocytosis in vivo,41 it did not cause trilineage hematopoietic progenitor cell hyperplasia.

Alternatively spliced forms of the erythropoietin receptor have been identified, one of which has a truncated cytoplasmic domain and was expressed at high levels in immature erythroid progenitor cells in contrast to the full-length receptor, expression of which increased with progenitor cell maturation.42 The function of the truncated receptor splice variant has been a matter of controversy.43,44 It was incapable of transmitting a signal but interfered with the proliferative activity of the full-length erythropoietin receptor44 while promoting differentiation.45 The truncated erythropoietin receptor splice variant was either not expressed well or at all in various erythroleukemia cell lines42,46 and its expression was also decreased or absent in polycythemia vera mononuclear cells.46 Since polycythemia vera erythroid progenitor cells differentiate more quickly than their normal counterparts,18 the significance of these observations with respect to the pathophysiology of the disease remains to be established.

Programmed cell death

The diverse and often conflicting observations concerning the behavior of polycythemia vera erythroid progenitor cells can be reconciled by the recent recognition that polycythemia vera erythroid progenitors overexpressed the antiapoptotic protein Bcl-xl and were resistant to apoptosis in the absence of erythropoietin.47Under normal circumstances, early erythroid progenitor cells are largely dormant and require erythropoietin as a mitogen to initiate their entry into cell cycle,48 while late erythroid progenitor cells which are largely cycling require only erythropoietin as a survival factor to allow completion of terminal differentiation.49 Erythropoietin deprivation results in cell cycle arrest in G0/G1,50 and down-regulation of expression of the antiapoptotic proteins Bcl-2 and Bcl-xl followed by programmed cell death.51 By contrast, overexpression of Bcl-2 or Bcl-xl allowed erythroid progenitor cells to maintain their viability while undergoing terminal differentiation in the absence of erythropoietin.51 

This behavior is not unique to erythroid progenitor cells, since multipotent hematopoietic progenitor cells overexpressing Bcl-2 not only remained viable in the absence of both growth factors and serum but were also able to undergo unrestricted lineage-specific commitment and terminal differentiation under these conditions as well.52 A significant feature of Bcl-2 overexpression was prolongation of the G1 phase of the cell cycle.52 Importantly in this regard, in vitro, the duration of G1 in erythroid progenitor cells appeared to be erythropoietin dependent; low concentrations of erythropoietin were associated with G1 prolongation and initiation of differentiation while high concentrations were associated with G1 shortening and cell proliferation.53 Thus, Bcl-xl overexpression could explain the accelerated differentiation of polycythemia vera erythroid progenitor cells in vitro in the absence of erythropoietin in contrast to their normal counterparts, as well as their survival advantage in vivo where erythropoietin production is suppressed, since both conditions promote G1 arrest and terminal differentiation. Therefore, the excess of erythroid cells that defines this disorder is more likely a consequence of cell accumulation than cell proliferation. This type of behavior is also consistent with and explains the incremental nature of the erythrocytosis in polycythemia vera (Figure 2) since only a fraction (5%-25%) of the erythroid progenitor cell population exhibited this behavior and its expression appeared to be random.17 Whether resistance to apoptosis in the absence of growth factors is a feature of myelopoiesis or thrombopoiesis in this disorder remains to be determined. One caveat with respect to this mechanism is that Bcl-xl expression is normally up-regulated with terminal erythroid differentiation54 and whether accelerated terminal erythroid differentiation in polycythemia vera was the cause of increased Bcl-xl expression or its consequence, and thus, whether another antiapoptotic mechanism might be involved, has not been established.

Fig. 2.

Rate of rise of the hematocrit level in a patient with polycythemia vera who sought treatment for the disease 9 years after the hematocrit level began to increase.

Adapted from Conley368 with permission of the publisher, The McGraw-Hill Companies.

Fig. 2.

Rate of rise of the hematocrit level in a patient with polycythemia vera who sought treatment for the disease 9 years after the hematocrit level began to increase.

Adapted from Conley368 with permission of the publisher, The McGraw-Hill Companies.

IGF-1

Insight into the mechanism for the resistance of polycythemia vera erythroid progenitor cells to apoptosis was provided by the observation that in the absence of serum, polycythemia vera erythroid progenitor cells were not more sensitive to erythropoietin than their normal counterparts. Rather, they were more sensitive to the antiapoptotic growth factor IGF-1.22 Furthermore, IGF-1 receptors on polycythemia vera peripheral blood mononuclear cells were constitutively tyrosine phosphorylated in contrast to those of normal blood mononuclear cells and also more sensitive to IGF-1.55 The serum concentration of IGF-1 binding protein-1 was increased in polycythemia vera patients and this protein was capable of stimulating erythroid burst formation in vitro.56 Importantly in this regard, it was recently demonstrated that cells expressing truncated erythropoietin receptors lacking their negative regulatory cytoplasmic domain and thought to be hypersensitive to erythropoietin36 were actually hyposensitive to the hormone in the absence of serum and hypersensitive to IGF-1.57 Thus, growth factor hypersensitivity in polycythemia vera could be a result of compensation for defective receptor-mediated signal transduction.

The thrombopoietin receptor, Mpl

Based on studies to date, the erythropoietin receptor cannot be implicated in such a process but the thrombopoietin receptor, Mpl, is a candidate. Mpl is expressed not only by megakaryocytes and platelets but also by pluripotent hematopoietic progenitor cells,58the survival of which is enhanced by the cognate ligand of Mpl, thrombopoietin.59 Thrombopoietin also acts synergistically with SCF and IL-3 to promote the proliferation of pluripotent hematopoietic stem cells,60 while impaired Mpl or thrombopoietin expression results in a reduction in the number of both multilineage and committed hematopoietic progenitor cells.61 Thrombopoietin in conjunction with SCF promotes the production of neutrophils from CD34+cells62 and in conjunction with erythropoietin, the production of erythroid progenitor cells,63 an effect that may be due to abrogation of apoptosis.64 Thrombopoietin overexpression in mice caused granulocytosis, thrombocytosis, osteomyelofibrosis with extramedullary hematopoiesis, and death,65 while ectopic expression of Mpl caused fatal erythroblastosis.66 Importantly, the retrovirus, MPLV, which encodes an Mpl gene truncated in its extracellular domain and fused with a viral envelope protein gene, induced a syndrome in mice that mimicked polycythemia vera,67 while hematopoietic progenitor cells infected with MPLV were growth factor–independent in vitro and capable of terminal differentiation in the absence of growth factors.68 Finally, Mpl expression and, therefore, its responsiveness to thrombopoietin in the megakaryocytes and platelets of polycythemia vera patients, were defective due to an as-yet-undefined impairment of its posttranslational glycosylation that became more profound with disease duration and extent.69These observations, taken together with the recent demonstration that removal of the Mpl distal extracellular cytokine receptor domain conferred growth factor–independent survival on hematopoietic cells expressing these truncated receptors,70 support the contentions that impaired hematopoietic growth factor receptor signaling has a fundamental role in the pathophysiology of polycythemia vera, that Mpl is a candidate receptor in this regard, and that polycythemia vera is a disorder of cell accumulation not cell proliferation.

The diagnosis of polycythemia vera: Osler's legacy; polycythemia vera is a clinical diagnosis

Diagnostic criteria

William Osler was not the first to describe a patient with polycythemia vera.3 He was, however, the first to emphasize that phenotypic mimicry could confound the diagnostic process and to propose clinical criteria to distinguish polycythemia vera from other disorders causing erythrocytosis71 (Table1). Remarkably, the Osler diagnostic criteria omit leukocytosis or thrombocytosis, an omission that may have diagnostic connotations as discussed below, but are otherwise similar to the major diagnostic criteria proposed by the Polycythemia Vera Study Group (PVSG) 6 decades later72 (Table 1). These diagnostic criteria are as important for what they do not specify as for what they do. First, bone marrow examination is not part of the diagnostic criteria. This is appropriate because bone marrow abnormalities, such as an increase in megakaryocytes and cellular hyperplasia with a loss of the fat spaces, while characteristic, can never alone be diagnostic for polycythemia vera,73 and if the other major PVSG diagnostic criteria are met, bone marrow examination is unnecessary. Furthermore, while nonrandom cytogenetic abnormalities and myelofibrosis have diagnostic implications, neither has prognostic implications74,75 and their frequency is too low to make bone marrow examination cost-effective. Even if bone marrow examination were diagnostic, that would still not abrogate the need for red cell mass and plasma volume determinations, tests that are justifiably cost-effective. Consequently, marrow examination is useful only when there is a change in the clinical course of the disease, for research purposes or for clinical trials. Yet, bone marrow aspiration and biopsy are frequently performed in the initial evaluation for polycythemia vera.7 This only confirms or generates an unexpressed fear of leukemia on the part of patients; a fear often validated by their physicians with respect to prognosis when in fact, with appropriate management, such an occurrence is only a remote possibility. Second, assays for erythropoietin and erythroid colony-forming cells are not part of the PVSG diagnostic criteria. While it can be argued that 30 years ago these tests were either insensitive or unavailable, it is equally easy to argue for the latter test that availability is still restricted clinically and that for both, specificity and sensitivity are unsatisfactory.

Table 1.

The diagnosis of polycythemia vera

1903* 1971 
 Erythrocytosis
 Cyanosis
 Splenomegaly 
 Elevated red cell mass
 Normal arterial 02saturation
 Splenomegaly
Plus any 2 below if no splenomegaly
 Leukocytosis greater than 12 000/μL
 Thrombocytosis greater than 400 000/μL
 Leukocyte alkaline phosphatase greater than 100
 Serum B12 greater than 900 pg/mL or unbound
 B12 binding capacity greater than 2200 pg/mL 
1903* 1971 
 Erythrocytosis
 Cyanosis
 Splenomegaly 
 Elevated red cell mass
 Normal arterial 02saturation
 Splenomegaly
Plus any 2 below if no splenomegaly
 Leukocytosis greater than 12 000/μL
 Thrombocytosis greater than 400 000/μL
 Leukocyte alkaline phosphatase greater than 100
 Serum B12 greater than 900 pg/mL or unbound
 B12 binding capacity greater than 2200 pg/mL 
*

From Osler.71 

From Wasserman.72 

Serum erythropoietin

The development of a sensitive and specific assay for circulating erythropoietin for the purpose of distinguishing autonomous from secondary erythrocytosis was long a holy grail of hematologists. Although we now have such an assay, it is an irony that due to the unique physiology of erythropoietin, measurement of the hormone in the circulation cannot be relied on to distinguish between autonomous and erythropoietin-driven erythrocytosis. This is because as the red cell mass expands, both improved tissue oxygenation and the associated increase in blood viscosity serve to depress erythropoietin production,76 while the plasma residence of erythropoietin is simultaneously reduced through increased catabolism by the expanded erythroid progenitor cell pool.77 The net result is that while the lowest erythropoietin levels occur in polycythemia vera14 (Figure 1), this is not absolute and a “normal” erythropoietin level is common in hypoxic erythrocytosis unless the hypoxia is extreme.78 Indeed, given the wide range of normal for serum erythropoietin (4 mU/mL-26 mU/mL), unless the premorbid serum erythropoietin level is known, a 6-fold elevation could occur without exceeding the normal range. Thus, while an elevated serum erythropoietin level suggests tissue hypoxia as a cause for erythrocytosis, a normal serum erythropoietin level does not exclude an hypoxic cause. Only an arterial oxygen saturation determination, as stipulated by the PVSG criteria, will suffice for this purpose.

Erythroid progenitor cell assay

Similarly, although erythropoietin-independent erythroid colony formation in vitro is characteristic of polycythemia vera15 and has been widely embraced as a diagnostic test for the disease, it cannot be recommended for this purpose. The reasons are many and cogent. Erythropoietin-independent erythroid colony formation is not specific for polycythemia vera. Although it is most obvious in this disorder, it can be seen in nonclonal causes of erythrocytosis79,80 and in healthy controls79,81 as well as in essential thrombocytosis.81-84 Furthermore, endogenous erythroid colony formation has been absent in some patients who meet the PVSG criteria for polycythemia vera.85 Part of the problem may be methodologic since the greatest specificity and sensitivity has been observed when bone marrow was used as the source for erythroid progenitor cells as opposed to peripheral blood and when erythroid colony-forming units (CFU-Es) were analyzed as opposed to erythroid burst-forming units (BFU-Es).86 The in vitro clonal assay for erythroid progenitor cells is also neither standardized nor widely available. For these reasons and because this assay does not establish clonality, it cannot be recommended as a routine clinical diagnostic test for polycythemia vera.

PVSG minor criteria

In an effort to improve diagnostic accuracy, particularly in the absence of splenomegaly, the PVSG added additional criteria such as the presence of leukocytosis and thrombocytosis. Approximately 60% of patients will not have both of these abnormalities initially4,87,88 nor will leukocyte alkaline phosphatase expression, serum vitamin B12, and unbound serum vitamin B12 binding capacity be uniformly elevated.88,89 

Impaired platelet Mpl expression

A number of other phenotypic abnormalities of the red cells (eg, microcytic erythrocytosis,90 increased hemoglobin F synthesis18), white cells (eg, increased surface expression of IgG receptors,91 impaired responsiveness to chemotactants92), and platelets (eg, reduced PGD2 receptor expression,93 impaired lipoxygenase generation94,95) have been observed in polycythemia vera but none of these abnormalities are either specific for the disease or suitable clinically for diagnostic use. Recently, impaired expression of the thrombopoietin receptor, Mpl, by the platelets of polycythemia vera and idiopathic myelofibrosis patients was documented96 and the severity of this defect correlated with the duration and extent of disease.69 A similar abnormality was not present in secondary erythrocytosis or chronic myelogenous leukemia (CML) but was present in some patients with essential thrombocytosis.97 Interestingly, recently the development of polycythemia vera or idiopathic myelofibrosis was observed in 3 of 4 essential thrombocytosis patients with reduced platelet Mpl expression,98 suggesting that the abnormality could have prognostic significance in this disorder. Whether impaired platelet Mpl expression will prove clinically useful for distinguishing polycythemia vera from other types of erythrocytosis or to identify polycythemia vera in the absence of erythrocytosis remains to be established. However, the consistency with which impaired platelet and megakaryocyte Mpl expression was observed in polycythemia vera patients96,99 suggests that it may be useful diagnostically.

PRV-1 expression

Recently, overexpression of the mRNA of a novel member of the uPAR receptor superfamily, designated PRV-1, was identified in polycythemia vera granulocytes by subtractive hybridization.89 This GPI-linked surface membrane receptor was detected only in normal granulocytes after exposure to granulocyte–colony-stimulating factor (G-CSF), was not expressed in the mononuclear cells from patients with secondary erythrocytosis, CML, or acute myelogenous leukemia (AML) and did not correlate with the expression of leukocyte alkaline phosphatase, another GPI-linked protein.89 Interestingly, like impaired Mpl expression, PRV-1 expression has also been detected in certain patients with essential thrombocytosis who also demonstrated in vitro erythropoietin-independent colony formation.100Quantitation of PRV-1 mRNA expression may also prove useful diagnostically in distinguishing polycythemia vera from other disorders causing erythrocytosis.

Clonality assays

The most important omission from the PVSG diagnostic criteria for polycythemia vera was a requirement for the establishment of clonality. Unfortunately, however, in contrast to CML, there has been no clinically applicable clonal assay for polycythemia vera or its companion myeloproliferative disorders, idiopathic myelofibrosis and essential thrombocytosis. Nonrandom chromosome abnormalities are not uncommon in these disorders and in polycythemia vera the most frequent are trisomies of 1q, 8, 9 or 9p, del13q, del20q, or interstitial deletions of 13 or 20; occasionally multiple defects are present.31,74,101,102 However, there is no consistent or unique cytogenetic abnormality associated with any of these disorders and at the time of diagnosis, using conventional cytogenetic techniques, less than 20% of polycythemia vera patients exhibit a cytogenetic abnormality and many patients never develop one.74 In this regard, the use of interphase fluorescence in situ hybridization (FISH) may increase the diagnostic yield.32 However, bone marrow aspiration is still required for cytogenetic analysis unless there are numerous primitive cells in the circulation.

In the absence of a specific and consistent cytogenetic marker, clonality assays in the chronic myeloproliferative disorders other than CML have been limited to genes on the X chromosome whose expression in women is subject to random inactivation. It was on this basis that the clonality of polycythemia vera was first established.1However, this type of clonal analysis is limited to women who are informative with respect to the expression of G-6PD isoenzymes or specific DNA polymorphisms. Expression of the former is restricted while the latter analysis is not informative in up to 30% of female patients103 and its utility is further limited by nonrandom, age-associated X-linked gene inactivation.104-106 Thus, although it has been clearly established as a general principle that polycythemia vera is a clonal disorder and represents the consequences of transformation of a multipotent hematopoietic progenitor cell, there is currently no way to establish clonality in the majority of patients considered to have the disease. While this is not an issue in patients exhibiting trilineage hematopoietic cell hyperplasia and extramedullary hematopoiesis, it is a critical issue in patients with erythrocytosis alone since in the absence of proof of clonality, it is difficult to justify the use of mutagenic drugs. Osler was well aware of the phenotypic mimicry that complicated the diagnosis of polycythemia vera71 and given the well-documented existence of unidentified and newly recognized nonclonal forms of erythrocytosis107,108 we would do well to follow his lead.

Measurement of the red cell mass and plasma volume

With respect to what the PVSG diagnostic criteria do stipulate, the most important is elevation of the red cell mass. Admittedly, this criterion does not establish clonality or even distinguish polycythemia vera from other disorders that cause erythrocytosis. However, it makes a vitally important point with respect to the evaluation of a high hematocrit level in general and polycythemia vera in particular—that only direct measurement of the red cell mass and plasma volume will suffice to distinguish absolute erythrocytosis from so-called spurious or relative erythrocytosis due to plasma volume contraction or red cell redistribution.109-111 Indeed, it is not hyperbole to state that failure to appreciate this basic concept has been responsible for more diagnostic and therapeutic failures in patients with polycythemia vera than any other single factor. The reason appears to be a lack of understanding of the pathophysiology of the red mass and plasma volume in disorders causing erythrocytosis.

Normally, the hematocrit or hemoglobin is maintained at a constant level that is characteristic for each individual but varies between individuals of the same sex by as much as 15% and between sexes by approximately 10%. As a corollary, erythropoietin production as represented by the serum erythropoietin level also remains constant.112 With tissue hypoxia, regardless of cause, as the red cell mass increases there is usually a concomitant reduction in plasma volume. Given the other factors involved in plasma volume regulation as well as in its measurement, the magnitude of plasma volume reduction reported with hypoxic erythrocytosis due to right-to-left cardiac shunts,113 impaired pulmonary gas exchange,114 carbon monoxide poisoning,115and low ambient oxygen tension116 varies but the downward trend is unmistakable. It should not be surprising, therefore, that therapy with recombinant erythropoietin,117 androgenic steroids,118 and even blood transfusion119also leads to a reduction in plasma volume; the mechanisms involved are unknown but may in part be protective since increasing whole blood viscosity suppresses endogenous erythropoietin production.76,120 By contrast, in polycythemia vera where erythropoiesis is autonomous and erythropoietin production is suppressed, as the red cell mass increases the plasma volume may be unchanged or increase121 until the hematocrit level is more than 60%.122 

Unfortunately, the hematocrit level, whether directly determined by centrifugation or calculated from the mean corpuscular volume (MCV) and the red cell count, will not reflect these changes because even under normal circumstances, the distribution of red cells and plasma is not uniform throughout the circulatory system.123-125Rather, as demonstrated by independent determinations of the red cell mass and plasma volume, the ratio of red cells to plasma is higher in the peripheral vessels, venous or arterial, than it is in the body as a whole (ie, whole body hematocrit derived from independent measurements of red cell mass and plasma volume/peripheral venous hematocrit = 0.92).126,127 This is a consequence of both the slower flow of the peripherally displaced plasma compared with the axial red cells and plasma skimming in the smaller vessels.123,125,128,129 With disease, changes occur in the plasma volume and red cell mass or in their distribution, particularly if there is splenomegaly121,130-132 that will not be evident by hematocrit level determination alone.109,133-136 Indeed, the assumption that the hematocrit accurately reflects the red cell mass or, stated differently, that the red cell mass:plasma volume ratio is constant in health and disease or even for all parts of the circulation, is simply incorrect and nowhere more so than when erythrocytosis is present.114,127,134,136 

Remarkably, although it was established in 1921123 and repeatedly confirmed125,126,137,138 that only by independently measuring the red cell mass (currently with51chromium) and the plasma volume (with125I-albumin) could an accurate assessment of each as well as the total blood volume be obtained, there is still resistance to this standard of practice. The reasons for this are several. First, the range of normal for such measurements, not unlike the range of the hematocrit, is wide, which affects their sensitivity. Consequently, only values more than 2 standard deviations (25%) above the mean are considered abnormal.139 Second, since adipose tissue has a low vascularity, red cell mass correlates better with lean body mass than body weight127 but, unfortunately, there is no simple method for clinically assessing lean body mass.111Therefore, if body weight in mL/kg is used as standard, the red cell mass will be underestimated in the obese,140 requiring correction factors based on weight.139 For these reasons and because of the need to use 2 radioisotopes, it has been variously advocated that the red cell mass be calculated from the plasma volume and the hematocrit141 by a mathematical formula based on the regression of the red cell mass on the hematocrit,142or dispensed with altogether on the grounds that the diagnosis of polycythemia vera is usually clinically apparent on the basis of other findings.143 None of these approaches are either physiologically sound or clinically acceptable because they rely on assumptions about the red cell mass:plasma volume ratio derived from measurements in healthy individuals that are not valid in disease.109,127 Simply stated, in disease, the red cell mass and plasma volume can vary independently of each other and it is no more possible to assess the red cell mass from the hematocrit than it is to determine total body sodium from the serum sodium concentration. Splenomegaly, of course, just compounds the problem.130-132,144 Stated differently, it is the author's opinion that whenever the diagnosis of polycythemia vera is considered, due to the potential of plasma volume expansion, a “normal” hematocrit value can never be considered normal and an independent determination of both the red cell mass and plasma volume by isotope dilution is mandatory for diagnostic and therapeutic purposes. Examples of the usefulness of red cell mass and plasma volume measurements in the evaluation of the cause of a high hematocrit level are shown in Table 2.

Table 2.

Examples of the diagnostic value of red cell mass (RCM) and plasma volume (PV) determinations

Disease Cases  
Pulmonary A-V shunt with hypoxemia Androgen therapy Polycythemia vera “Idiopathic myelofibrosis”  
Age, y/sex, M/F 50/M 52/M 68/F 49/F 
1.85 2.15 1.64 1.50  
Hematocrit, % 58.4 56.4 47.0 41.5  
Expected* and observed values     
 RCM, mL 1924, 3982 2370, 2661 1420, 2217 1284, 2581  
 PV, mL 2919, 2499 3393, 1824 1288, 2500 2095, 3545  
 TBV, mL 4843, 6481 5763, 4485 3708, 4717 3379, 6126 
Disease Cases  
Pulmonary A-V shunt with hypoxemia Androgen therapy Polycythemia vera “Idiopathic myelofibrosis”  
Age, y/sex, M/F 50/M 52/M 68/F 49/F 
1.85 2.15 1.64 1.50  
Hematocrit, % 58.4 56.4 47.0 41.5  
Expected* and observed values     
 RCM, mL 1924, 3982 2370, 2661 1420, 2217 1284, 2581  
 PV, mL 2919, 2499 3393, 1824 1288, 2500 2095, 3545  
 TBV, mL 4843, 6481 5763, 4485 3708, 4717 3379, 6126 
*

The “expected” values were derived using the formulas from Pearson et al.139 These 4 examples illustrate that it is not possible to predict the red cell mass from the hematocrit alone and that in polycythemia vera a normal hematocrit value does not ensure that the red cell mass is normal. In hypoxic erythrocytosis, the red cell mass expands at the expense of the plasma volume; with androgen therapy, there is often a reduction in the plasma volume which gives the false impression that erythrocytosis is present. In polycythemia vera, expansion of the plasma volume can mask expansion of the red cell mass; in the case of the 49-year-old woman, splenomegaly masked the elevated red cell mass and for at least 8 years she was thought to have idiopathic myelofibrosis.

Adapted from Handin et al369 with permission of the publisher, Lippincott, Williams, and Wilkins.

Anecdote as paradigm: the natural history of polycythemia vera has not yet been defined

The description of the natural history of polycythemia vera in current hematology textbooks disguises the fact that little more is known today about its clinical course than was known 80 years ago. Attempts to define the natural history of polycythemia vera then as now have been frustrated not only by the low incidence of the disorder but also its chronic nature which precludes most physicians from seeing more than a few of these patients or even following them for a sufficient duration to encounter the full scope of the disease. These factors coupled with an initial lack of appreciation of the effect of radiation or chemotherapy on bone marrow function led to the acceptance of anecdotal case studies as representative of the natural history of polycythemia vera.

The natural history hypothesis

In 1954, based on such anecdotal reports, a hypothetical description of the natural history of polycythemia vera was proposed by Wasserman according to which the disease evolved through a series of clinical stages beginning with an asymptomatic phase and proceeding through erythrocytotic, compensated or inactive, and spent or postpolycythemic myeloid metaplasia phases before terminating in acute leukemia if death from another cause did not intervene first.145 Given the similarity of this proposed natural history to that of CML, it is not surprising that without either testing or debate, the status of dogma was promptly conferred on this hypothetical description, and for the past 46 years it has been reiterated unchanged in greater or lesser detail in virtually every major hematology textbook when in fact the clinical data from which it was derived fail to meet the lowest standard of evidence-based medicine. Indeed, the basis for this concept of the natural history of polycythemia vera was a 1938 publication by Rosenthal and Bassen describing 13 patients from a series of 75 who were thought to be representative of the various hematologic manifestations of the disease.146 Of the 13 patients. 2 were anemic and thereby thought to manifest the so-called “spent” phase of the disorder, a concept first proposed by Minot and Buckman.147 Both, however, had previously been treated with radiation therapy.

Dameshek had earlier proposed a similar natural history scheme148 but qualified his proposal as follows: “it is difficult to state what the ‘normal’ course of the disease would be without the various therapeutic methods which undoubtedly influence it.” Unfortunately, this caveat was disregarded and only rarely have polycythemia vera patients been followed long enough without exposure to therapeutic interventions such as radiation or 32P that significantly alter bone marrow function for any meaningful appreciation of the natural history of the disorder to be obtained. When this has been achieved, a different picture of the disease emerges.149,150 Additionally, it is not widely appreciated that the disease may have different manifestations depending on the age at onset and the patient's sex.151 Finally, adding to the confusion has been the uncritical acceptance or misuse of terms such as “spent phase” and “postpolycythemic myeloid metaplasia” together with the assumption that the various chronic myeloproliferative disorders are interrelated152 when in fact proof is lacking that they are.153 

The spent phase of polycythemia vera

While it has been clearly established that polycythemia vera can be complicated by anemia, myelofibrosis, and myeloid metaplasia, the frequency with which these complications occur and their clinical significance in the absence of cytotoxic therapy has rarely been ascertained prospectively. For example, the development of anemia due to bone marrow exhaustion has been considered an inevitable event in the natural history of polycythemia vera and possibly a forerunner of leukemia.145,154 As mentioned above, it was in this context that the term “spent phase” was initially used.147 However, in a large series of polycythemia vera patients managed without radiation therapy, anemia was most often due to chemotherapy, hemorrhage, deficiency of iron, folic acid or vitamin B12, or another disease and not to intrinsic marrow failure.149 Importantly, the role of iron deficiency as a cause for anemia was not recognized in early descriptions of the disease,147 nor was it appreciated that the plasma volume expansion associated with splenomegaly could mask the true red cell mass. Furthermore, in some patients, the “spent phase” proved to be reversible with therapy.150When these facts, together with ferrokinetic studies in patients with advanced disease155 are taken into account, it is clear that that there is not necessarily an irreversible exhaustion of erythropoiesis with disease progression or duration and that while the frequency with which refractory anemia is a direct consequence of polycythemia vera remains to be established, from the available data, it appears to be uncommon.156,157 More important than the so-called spent phase is the peculiar wasting syndrome that can develop late in the course of polycythemia vera in which intractable weight loss is associated with extramedullary hematopoiesis and substantial elevation of the white cell and platelet counts.

Finally, the term “spent phase” as used today also appears to mean different things to different authors. Initially and still employed to denote the progression of polycythemia vera to a state of bone marrow failure and possibly a prelude to leukemia145,146 it has also been used to describe a phase of polycythemia vera with splenomegaly without either myelofibrosis or myeloid metaplasia in which erythrocytosis continues unabated with its extent masked by plasma volume expansion.136 As indicated above, the former use of the term has never been authenticated in a scientifically acceptable fashion and the latter use, of course, is actually contradictory since in the type of patients described, bone marrow function was actually robust.155,158 Furthermore, such patients have also been described by others as being in the “stationary phase” of the disease,148 a designation that is equally improbable since no evidence has been provided that disease activity has changed. All of this only serves to illustrate the confusion that results when anecdotal experiences are uncritically elevated to the status of paradigm and medical jargon is substituted for medical judgment. In a disease such as polycythemia vera, anecdotal case reports are invaluable for defining what is possible but only prospective longitudinal studies of well-defined patient cohorts can establish what is probable.

Myeloid metaplasia

This conclusion also applies to 2 other complications of polycythemia vera, myeloid metaplasia and myelofibrosis. Since splenomegaly in polycythemia vera is initially due to red cell congestion,13,159-161 without a tissue biopsy, the assumption that splenic enlargement represents extramedullary hematopoiesis could be erroneous.133,162 It is probably for this reason that estimates of the frequency of myeloid metaplasia, based on the presence of immature myeloid and erythroid cells in the circulation or organomegaly, have varied from 7% to 14%.75,145,157,163 Furthermore, the widely used term “postpolycythemic myeloid metaplasia”164 is more than imprecise; it is an oxymoron since it implies that myeloid metaplasia is a terminal complication or conversion of polycythemia vera to another disorder rather than being an integral component of the disease itself165 that may not shorten survival.75,166,167 It also implies that bone marrow activity is impaired when in fact, in the absence of radiation or chemotherapy, there is no correlation between the extent of extramedullary hematopoiesis and bone marrow hematopoietic activity in polycythemia vera.168 

As originally used, “postpolycythemic myeloid metaplasia” was a synonym for the spent phase of polycythemia vera in which the predominant features were myeloid metaplasia, splenomegaly, myelofibrosis, and anemia.164 However, as indicated above with respect to anemia, there have been few attempts to analyze the influence of radiation or chemotherapy on the development of “postpolycythemic myeloid metaplasia” but when this has been done, the majority of patients fitting this description have been exposed to agents toxic to the bone marrow.163,164,169 Thus, a century after the description of polycythemia vera, judgment must remain suspended as to the frequency with which bone marrow failure is a terminal feature of this disease in the absence of an exogenous cause but published data suggest that it is not high.157 

Myelofibrosis

Given the above, it should not be surprising, therefore, that substantial misconceptions also exist with respect to significance of myelofibrosis in polycythemia vera. This is because the mechanisms for myelofibrosis are poorly understood170-172 and the means for quantitating it imprecise due to the patchy nature of the process.168,173-175 Furthermore, with respect to diagnosis, it has generally been assumed that polycythemia vera and idiopathic myelofibrosis are closely related disorders,152although apart from phenotypic similarities, this assumption has never been substantiated scientifically. Indeed, some investigators have considered the development of myeloid metaplasia and myelofibrosis in polycythemia vera as indicating the onset of a “transitional myeloproliferative disorder”135 rather than part of the natural history of the disease, while others have considered erythrocytosis to be a complication of idiopathic myelofibrosis.134 The development of myelofibrosis per se in the setting of polycythemia vera has also been considered to have adverse prognostic implications,176 another erroneous assumption.75,150,156,174,177 

Because there is no widely accepted standard for the quantitation of marrow reticulin158 nor a universally acknowledged definition for the term “myelofibrosis” outside the setting of the disease, idiopathic myelofibrosis,178 it is difficult to obtain a precise frequency for its occurrence in polycythemia vera as well as the impact of therapy on this. Within the limitations of these data, it appears that increased marrow reticulin is part of the natural history of the disease, presumably reflecting in part the increase in marrow cellularity158,179 and possibly disease duration.180 However, an increase in marrow reticulin, or even osteosclerosis, is certainly not synonymous with a “spent” phase75,134,135,155,158,181-183 and can be modified to a certain extent by therapy,75 particularly with busulfan.182,184 Spontaneous regression of myelofibrosis has also been observed,168,175,182,185,186 although the patchy nature of the process makes this observation as difficult to substantiate as the contention that myelofibrosis is a progressive and destructive process.173-175,187 

If studies of idiopathic myelofibrosis patients can be used as a guide, myelofibrosis and osteosclerosis are not usually progressive processes.168,174,188 There does, however, appear to be a higher incidence of “myelofibrosis” in polycythemia vera patients exposed to either radiation or chemotherapy than those treated by phlebotomy alone, 8.4%156,163,164,173,189 versus 4.5%,149,156,163 but there is not absolute agreement on this point.75,176 As a corollary, in studies of idiopathic myelofibrosis, polycythemia vera patients comprised 16% (range, 7%-38%) of the patients and most had been treated with radiation or chemotherapy.173,175,177,190-193 To the extent that it has been evaluated, marrow reticulin was increased in 8% to 15% of polycythemia vera patients at the time of diagnosis,73,181,194,195 a finding that appeared to have no prognostic significance.75,150,167 This is in contrast to development of myelofibrosis in CML, which is generally associated with disease acceleration.196 Taking everything together, while it is clear that the hematologic manifestations of polycythemia vera include myeloid metaplasia and myelofibrosis, it is not yet established that these processes indicate terminal bone marrow failure or that marrow failure is an inevitable consequence of the disease in the absence of cytotoxic therapy. Certainly, given the limitations of the data upon which the current concept of the natural history of polycythemia vera is based, it is time to abandon uncritical and unphysiologic terms such as “stationary,” “spent,” “transitional,” and “postpolycythemic myeloid metaplasia” in favor of descriptions based on quantitative, prospective, and biologically sound observations.

Acute leukemia: relationship to therapy

The relationship between polycythemia vera and acute leukemia also requires clarification because it is central to the management of polycythemia vera. In 1950, Schwartz and Ehrlich reviewed the published evidence that acute leukemia was a feature of polycythemia vera in the absence of exposure to mutagenic therapy.197 Of 83 published cases, only 30 had unequivocal evidence of polycythemia vera preceding the development of acute leukemia and 25 of these patients had been irradiated. Of the remaining 5 patients, data supporting the absence of radiation exposure were available for only one. Since the criteria employed by Schwartz and Ehrlich for the diagnosis of polycythemia vera and the diagnosis of acute leukemia were stringent, it is ironic that in the one case of polycythemia vera that they accepted as spontaneously developing acute leukemia, the diagnosis was not histologically confirmed.146 They also emphasized the association of the newly introduced 32P therapy with acute leukemia in polycythemia vera patients and correctly predicted that this complication would increase in frequency. By contrast, the advocates of 32P therapy thought that the development of acute leukemia was an inevitable consequence of extended patient survival.133,198 

Modan and Lilienfeld's landmark 1965 paper unequivocally demonstrated that the leukemogenic effect of irradiation or 32P was not a consequence of prolonged survival,163 but the impact of their observations was blunted by the report of Halnan and Russell in which the incidence of acute leukemia in 32P-treated polycythemia vera patients was negligible.199 Any doubt about this issue, however, was eliminated by the PVSG-01 trial which established that therapy with either 32P or the alkylating agent, chlorambucil, resulted in an incidence of acute leukemia far exceeding that observed with phlebotomy alone without prolonging survival.200 The apparent conflict between the Modan and Lilienfeld data and that of Halnan and Russell was in part due to study design, since the mean time of onset of 32P-induced acute leukemia is approximately 8.5 years201 while most of Halnan and Russell's patients were followed for only 5 years, and in part to differences in radiation dose. Parenthetically, this episode serves to remind us that the absence of evidence is not proof of its absence.

Polycythemia vera has the dubious distinction of being the first hematologic malignancy and only the third disorder temporally—ankylosing spondylitis202 and thymic enlargement203 being the other 2—in which an association between acute leukemia and therapeutic irradiation was identified.197 Unfortunately, acceptance of the leukemogenicity of irradiation in polycythemia vera was delayed by the belief that leukemia was an inevitable feature of the disease.145,154,204 As a consequence, practitioners in this area were denied an essential paradigm to guide their therapy until similar observations had been well established for other hematologic205 and nonhematologic neoplasms.206 Importantly, from a biologic perspective, the leukemogenic effect of irradiation or alkylating agents in polycythemia vera was neither qualitatively nor quantitatively different from that observed for other neoplasms treated in the same fashion with respect to drug or radiation exposure, latency, type of leukemia, cytogenetic abnormalities, and response to treatment.180,207,208 Although data have been presented suggesting that myeloid metaplasia and myelofibrosis predispose to acute leukemia in polycythemia vera,145,193,209 this contention remains controversial since the number of patients involved was small and the observations were not confirmed in other studies.163,167,180 Furthermore, therapy-induced acute leukemia has also been observed in patients with secondary erythrocytosis mistakenly treated with chemotherapy or radiation.163,210,211 These considerations are not trivial since they speak to the larger underlying issue of the spontaneous development of acute leukemia in polycythemia vera.

Spontaneous acute leukemia: Richter syndrome revisited

In contrast to the well-established body of data on treatment-induced acute leukemia in polycythemia vera,163,180,197,200,207,212-214 few data exist other than anecdotal case reports with respect to the spontaneous occurrence of acute leukemia. As mentioned above, up to 1950, Schwartz and Ehrlich accepted as valid only one published report describing such an event.197 In the same year, Dameshek reported that one of his 50 patients and 2 of 100 Mayo Clinic patients treated only by phlebotomy had developed acute leukemia.148 Since then there have been 12 individually published case reports215-217 and an additional 11 patients identified by questionnaire215 in whom acute leukemia complicated polycythemia vera in the absence of irradiation or chemotherapy, while in 4 published series comprising 505 patients, 3 cases of spontaneous acute leukemia were observed.149,156,163,218Demographically, these patients are of interest because 90% were men with a mean age of 60.5 years, in contrast to those developing acute leukemia following alkylating agent therapy, of whom 54% were men with a mean age of 52.5 years. The interval for the former group between the onset of polycythemia vera and acute leukemia was 4.8 years (range, 1-13 years) and in the chemotherapy-treated group 6.7 years (range, 1-20 years), but these latter data are not comparable because the time of initiation of alkylating agent therapy relative to the onset of the polycythemia vera was not defined. It is also of interest that 3 of the 10 patients in the spontaneous leukemia group for whom the information was available had undergone splenectomy 2 to 8 years before the onset of the leukemia.193,219 Finally, in contrast to the chemotherapy-treated patients, patients developing spontaneous acute leukemia could still have concomitant erythrocytosis and only partial bone marrow transformation at the time that the leukemia was recognized.220 

Second cancers occur more often than can be explained by chance in patients already afflicted by a malignancy221 but with the exception of exposure to radiation, radiomimetic drugs, or a combination of these, the mechanisms involved are undefined. With respect to the development of secondary acute leukemia, age, disease stage, type of cancer,221 and immunologic status including the postsplenectomy state222-225 have all been considered to have a role. In some instances, the development of myelodysplasia or acute leukemia could even be considered a paraneoplastic syndrome226,227 since there is precedent for the cytokine-driven development of acute leukemia.228 With respect to polycythemia vera, given the increasing incidence of acute leukemia with age,5 the mean age of polycythemia vera patients, and the restoration of the polycythemic state with successful remission induction therapy,220,229,230 the possibility of a chance occurrence cannot be excluded particularly with the simultaneous presence of both disorders.229 At the same time, given the evidence of clonal evolution or succession in polycythemia vera,74 the possibility of leukemia arising from the malignant clone is also likely. The role of splenectomy is intriguing since this has been implicated in the evolution of acute leukemia in idiopathic myelofibrosis223 although the observation remains controversial.231 

Importantly, the polycythemia vera patients with spontaneous acute leukemia described to date differ from those with treatment-induced acute leukemia not only by their male predominance but also by their age at onset and the short interval between the diagnosis of polycythemia vera and the development of acute leukemia, thereby excluding prolonged survival, myeloid metaplasia, or myelofibrosis as antecedent factors as claimed.209,218 In fact, the situation is similar in many respects to Richter syndrome, in which chronic lymphocytic leukemia is complicated by either the development of a diffuse large cell lymphoma or transformation to prolymphocytic leukemia.232 These uncommon events can occur in untreated patients without regard to disease duration and may arise from either the original malignant clone or one immunologically distinct.233 However, regardless of mechanism, the important point is that the spontaneous development of acute leukemia in polycythemia vera is uncommon and certainly not inevitable, and our patients deserve to know this.

Survival with polycythemia vera: hematology's second amendment privilege

Probably no myth has been more pernicious with respect to the well being of polycythemia vera patients than the myth of survival which exists in 2 versions. It is difficult to understand how this myth attained credibility since there were both anecdotal reports185,234,235 and observational series146,147,149,236 that firmly established the prolonged survival of polycythemia vera patients in an era when the mainstays of therapy were phlebotomy, phenylhydrazine, and sporadic irradiation. Unfortunately, these observations were ignored in favor of the first version of the myth which arose from the assumption that leukemia was an inevitable feature of polycythemia vera.198 This position was stated most emphatically by Osgood,237 “…for any treatment the benefits to be obtained must be weighed against the risks incurred. Most patients would rather die at an advanced age with some risk of leukemia than at an earlier age from some other cause.” However, no patients appear to have been polled about this contention but it would be more realistic to conclude that most would rather die at an advanced age with no risk of leukemia.

The second version derived from an early attempt to study survival in polycythemia vera in a systematic fashion. In 1962, Chievitz and Thiede reviewed the causes of death in 250 Danish polycythemia vera patients. Among their conclusions were the following: “Out of the untreated patients, 50% had died 18 months after the onset of the first symptom or sign, and out of patients treated with venesection half had died 3 1/2 years after this juncture. Out of patients treated by X-rays half were alive 12 1/2 years after the first sign.”156 This article was one of the first to report survival data and has been the rationale for the implementation of various treatments for polycythemia vera without provision for the inclusion of the appropriate phlebotomy control group.238And this was true even though 12 years previously, another Danish physician, Videbaek, reporting on a series of 125 patients, noted a 50% survival of 4.5 years for men and 8.5 years for women treated with phlebotomy or irradiation but not 32P.239Indeed, Videbaek came to the conclusion that “…a large proportion of the high mortality which is known to attend polycythemia vera is not due to inadequacy of the therapeutic measures, but rather to the fact that the patients are not followed up as they should be,” a point ignored not only by Chievitz and Thiede but also by many in the hematology community.201,240-242 

The differences between the experience of Videbaek and that of Chievitz and Thiede can be explained in part by the fact that more than twice as many of the patients in the latter series were older than 65 years and age of onset appears to influence survival.215 At the same time, Videbaek's patients undoubtedly had less access to medical care, which was also likely to have been of a lower standard, making the differences in survival even more striking. Furthermore, as stated previously, the literature contains sufficient other support for the contention that the clinical course of polycythemia vera, without treatment or treatment mainly by phlebotomy, was not as dismal as described above.149,150 Therefore, it is difficult to explain the universally uncritical acceptance of Chievitz and Thiede's conclusions except on the grounds that they either suited the prejudice of those who were enamored of particular therapies such as32P204,237 or provided hematologists with the same type of “constitutional privilege” with respect to the treatment of polycythemia vera200,201,243,244 that is invoked by those American citizens who support the right to bear arms without restriction. Indeed, even today, there are advocates of32P therapy,201,245 although it has been widely appreciated for 50 years that this agent was least effective against the most troublesome feature of polycythemia vera, extramedullary hematopoiesis.167,189,246 

Central to the myth of survival is the assumption that polycythemia vera is a monolithic disease when in fact it is not122,146,246,247 and while no one would advocate withholding treatment once the diagnosis was established, it is important to emphasize that the disease can develop gradually and be substantially advanced before it becomes clinically problematic (Figure2). Presumably, this is a consequence not only of the slow rate of hematopoietic cell accumulation but also the concomitant compensatory expansion of the plasma volume. The occurrence of a preclinical or asymptomatic phase was first documented by Rosenthal and Bassen,146 confirmed by Dameshek,148 and calculated to be between 17 and 80 months by Swolin et al based on the rate of accrual of cytogenetic abnormalities.74 The Gruppo Italiano Studio Policitemia documented a significant incidence of thrombosis more than 2 years before the diagnosis of polycythemia vera,244 as did the PVSG,248 and in another study, 11 of 13 patients with an intraabdominal venous thrombosis had an elevated hematocrit level for 6 or more months before onset of thrombosis,249 also supporting a significant latent period even in symptomatic patients. Finally, Rozman et al250 and others251 have presented data suggesting that the life expectancy of polycythemia vera patients in the modern era was not greatly different from normal. Since both retrospective163and prospective controlled clinical trials have established that radiation or chemotherapy did not prolong life more than phlebotomy,200 and that the course of polycythemia vera is generally indolent, its management should be in keeping with its tempo and not with what we should acknowledge to be historical inaccuracies.

Phlebotomy and polycythemia vera: women are not small men

Thrombosis and hemorrhage in polycythemia vera

Erythrocytosis not only distinguishes polycythemia vera from its companion myeloproliferative disorders but is also responsible for its most frequent and serious complications. Published data indicate that thrombosis was the presenting feature in 12% to 49% of patients,133,149,156,194,239,244,252,253 occurred in up to 40% during the course of the illness,194 and was the cause of death in 20% to 40%.145,149,156,239,244,254Furthermore, in 2 studies, 14% to 15% of patients had a history of a thrombotic event at least 2 years before diagnosis.244,248In general, the central nervous system was the most frequent site of thrombosis,156,244,253,255 arterial thrombosis was more common than venous156,244,253-255 and the latter was characteristically cerebral or intraabdominal and more frequent in women,151,194,241 possibly in keeping with their higher incidence of splenomegaly at presentation.239 Indeed, polycythemia vera was the most common cause of hepatic vein thrombosis in the Western hemisphere.256 Finally, although not as frequent as thrombosis, hemorrhage in polycythemia vera was generally considered to be a consequence of vascular stasis and thrombocytosis133,149,257 and like thrombotic events, primarily involved the central nervous system and the gastrointestinal tract, was a presenting manifestation in 6% to 58% of patients149,156,194,239 and fatal in up to 30.149,156,239,254 

Whole blood viscosity

The mechanisms involved in the hypercoagulable state that characterizes polycythemia vera are currently still under scrutiny258 even though they were apparent to the first clinicians to study the disease. The hematocrit is the principal determinant of blood viscosity259-261 and nowhere is this more evident than in polycythemia vera. Perhaps the most cogent observation in this regard was made by Weber in 1908, “In every case examined after death the distention of the visceral vessels has been very striking, the mesenteric vessels presenting sometimes the appearance of having been forcibly injected for purposes of anatomical demonstration.”262 Brown and Giffin added to that description in 1923 with their study of nail-fold capillaries, which were elongated and engorged to capacity due to the formation of red cell aggregates, leading to diminution of blood flow that was most marked in the venous limb.263 Since cardiac output was either normal or increased in polycythemia vera patients due to an increased stroke volume,264,265 the diminution in capillary flow appeared to represent the influence of both peripheral vasodilatation and increased blood viscosity. In this regard, it needs to be emphasized that major vessel venous thrombosis in polycythemia vera most likely represents the end stage of a process beginning in very small vessels.266 These observations are also compatible with the preponderance of thrombotic events in the brain and the abdomen. In the former, an increase in hematocrit was associated with a decrease in blood flow,267-269 while the latter appears to be particularly vulnerable to disorders conducive to stasis or endothelial damage such as sickle cell anemia or paroxysmal nocturnal hemoglobinuria.

Although it has been argued that the decrease in cerebral blood flow associated with a high hematocrit level is a physiologic response to increased oxygenation not increased viscosity,270 the data upon which this contention are based either actually support the latter process270,271 or fail to substantiate the former since the subjects studied were actually not sufficiently hyperviscous.272,273 On the contrary, there are physiologically sound data indicating that cerebral blood flow like blood flow elsewhere274 declines independently of oxygen transport when blood viscosity increases.275 

Blood viscosity is an exponential function of the hematocrit259 and red cell aggregation increases at high hematocrit levels,276 creating the potential for vascular stasis if red cell production is left checked. While no other mechanism for thrombosis need be invoked in this circumstance, other mechanisms could contribute. Thus, increasing the hematocrit at flow rates found in the arterial circulation enhanced platelet-vessel wall interactions277 and this mechanism could be involved in the high incidence of arterial thromboses without requiring an elevation in platelet count.255 Additionally, a high hematocrit level has also been found to interfere with the vasodilatory effects of nitrous oxide278 which could account for the hypertension associated with polycythemia vera133,149,239,279 as well as its thrombotic tendency. Leukocytes can impede red cell migration in capillaries,280 interact with platelets at the vessel wall,281 and appear to be activated in polycythemia vera,282,283 but their role in the thrombotic process remains undefined because polycythemia vera patients treated with chemotherapy did not have a greatly diminished risk of thrombotic events.200 Finally, although impairment of the fibrinolytic system284 and platelet activation285 have been observed in polycythemia vera patients, such defects were not limited to this myeloproliferative disorder. For example, spontaneous platelet aggregation was most marked in patients with idiopathic myelofibrosis286 who were more prone to hemorrhage than thrombosis.287 Finally, there is no evidence that other coagulation defects predisposing to hypercoagulability are more prevalent in polycythemia vera patients than in the general population, although they are certainly not immune to them.288,289 

Phlebotomy therapy: pros and cons

Not only is there compelling evidence that increased blood viscosity due to an elevated red cell mass is the principal basis for the hypercoagulable state in polycythemia vera, there is equally strong evidence that phlebotomy, a venerable practice that was well known in the Hippocratic era, is the most effective remedy. Unfortunately, it is both an irony and a tragedy that this is one Hippocratic principle that many hematologists have been reluctant to embrace wholeheartedly. The reasons are many but none are clinically tenable or physiologically sound. First, although phlebotomy was recognized by early clinicians as an effective method of bringing symptomatic relief to polycythemia vera patients, the adequate or consistent application of phlebotomy was deterred by the concern that it would stimulate new blood formation. Thus, in 1928, an authoritative review of the disease stated “One must conclude that while venesection is an important and useful in relief in emergency in the treatment of these patients, it cannot be looked upon in any other light than as a further, and therefore undesirable stimulant to new blood formation.”159 This contention, reaffirmed more than once in modern times in the absence of any data,87,145,148,290 is, of course, erroneous, since bone marrow function in polycythemia vera, as in the other myeloproliferative disorders, is autonomous and erythropoiesis can neither be suppressed by hyperoxia10,291 nor substantially stimulated by hypoxia292 or phlebotomy,12,13,293 and this appears to be true for thrombopoiesis as well in the absence of anemia.150,182,293-295 

Second, it has been contended that phlebotomy provokes hypercoagulability. As stated by Osgood, “The major risks from phlebotomy are that it sets in motion all the clotting mechanisms plus suddenly reducing blood volume and possibly slowing the blood current and results in increased risk of thromboses and iron deficiency.”238 All aspects of this contention are indefensible. First, to the extent that any form of erythrocytosis provokes a hemorrhagic diathesis, phlebotomy restores coagulant activity toward normal by reducing blood viscosity296,297and thereby improving blood flow, platelet function,298,299 and the balance between coagulation factor concentration and red cell number, and this is as true in polycythemia vera133,300 as in the erythrocytosis of cyanotic congenital heart disease.301 Second, in contrast to 32P therapy, venesection actually expands the plasma volume and thus results in a greater reduction in blood viscosity for any reduction in red cell mass than the former297 (Table3). Paradoxically, this effect of venesection is also observed in pseudoerythrocytosis in which the plasma volume is reduced,302 an effect not always recognized.110 Moreover, in addition to a direct reduction in total blood volume, plasma volume expansion is another relatively immediate effect,303 making phlebotomy at once both corrective and protective. Finally, the effectiveness of venesection in relieving symptoms due to an elevated red cell mass has been repeatedly documented in patients with secondary forms of erythrocytosis.304-307 

Table 3.

Effect of 32P therapy or phlebotomy on the plasma volume and systemic vascular resistance in polycythemia vera

Measurement Therapy 
32Phlebotomy 
Before After Before After  
Systemic vascular resistance,
dynes s cm−5 
1421 19903-150 1504 1464  
Red cell mass, mL/kg 57.3 28.43-150 54.8 39.53-150 
Plasma volume, mL/kg 37.0 39.3 38.5 48.73-150 
Total blood volume, mL/kg 94.3 67.63-150 93.3 88.23-150 
Hematocrit, % 64.0 44.03-150 63.0 47.03-150 
Hemoglobin, gm% 19.9 14.93-150 19.9 14.93-150 
Measurement Therapy 
32Phlebotomy 
Before After Before After  
Systemic vascular resistance,
dynes s cm−5 
1421 19903-150 1504 1464  
Red cell mass, mL/kg 57.3 28.43-150 54.8 39.53-150 
Plasma volume, mL/kg 37.0 39.3 38.5 48.73-150 
Total blood volume, mL/kg 94.3 67.63-150 93.3 88.23-150 
Hematocrit, % 64.0 44.03-150 63.0 47.03-150 
Hemoglobin, gm% 19.9 14.93-150 19.9 14.93-150 

In contrast to phlebotomy therapy, 32P not only reduced the red cell mass but also the plasma volume, resulting in an increase in systemic vascular resistance even though the red cell mass was reduced to normal. Elevation of the plasma volume by phlebotomy expanded the total blood volume and reduced systemic vascular resistance even though phlebotomy therapy in these patients was insufficient to reduce the red cell mass to normal. Noteworthy for the phlebotomy group is that the hematocrit and hemoglobin levels were apparently normal even though the red cell mass was still increased due to masking by the expanded plasma volume. The data are from Segel and Bishop.297 

F3-150

Significantly different from before therapy (P < .01).

Iron deficiency and whole blood viscosity

Concerns over the adverse effects of phlebotomy-induced iron deficiency relate to both its side effects and the potential for increased blood viscosity.308,309 The former concern was addressed by exercise studies of chronically iron-deficient polycythemia vera patients in whom no impairment of aerobic capacity was detected,310 nor were functional signs of iron deficiency observed other than the gustatory perversion pica.311 Iron deficiency–related hyperviscosity is a test tube artifact308,309 that also has no physiologic basis.312,313 Although iron-deficient red cell membranes may be less deformable than normal,314 this abnormality is apparently offset by their reduced size and internal viscosity since their hemoglobin content is also reduced.315 Thus, at comparable hematocrit levels, iron-deficient blood was not more viscous than normal.312,313 Furthermore, red cell–platelet interactions are influenced by red cell diameter and such interactions are reduced with small red cells.315 Finally, a state of chronic iron deficiency that limits erythropoiesis is actually the ultimate goal of phlebotomy therapy in polycythemia vera, a goal that is unfortunately frequently not achieved judging from published results.156,200,239,244 

Phlebotomy and myelofibrosis

A more serious claim has been that the use of phlebotomy therapy alone in polycythemia vera results in a high incidence of myelofibrosis,316 a claim that is difficult to understand except as population specific since it is contrary to most published experience. For example, in a series of 207 patients followed for more than 10 years, only 4 patients treated solely by phlebotomy developed myelofibrosis,149 while in another series of 250 patients, none of the patients treated solely by phlebotomy developed myelofibrosis.156 Indeed, this experience has been the rule148,156,163 rather than the exception. As a corollary, the low incidence of polycythemia vera patients recorded in a published series of myelofibrosis patients173,175,190,192 as well as the high incidence of myelofibrosis observed in patients treated with hydroxyurea169 suggest that this complication is neither frequent nor limited to patients exposed only to phlebotomy. Furthermore, since myelofibrosis can be a presenting manifestation of polycythemia vera73,317 and also occurs in patients exposed to 32P163,189,318 and x-ray therapy,156,163,234 there are no grounds to implicate venesection as a specific causal factor. An additional difficulty in this regard, as discussed above, is the definition of myelofibrosis; a dry tap or increased reticulin is not sufficient for this purpose.158,179 Finally, implicit in this contention is the notion that myelofibrosis is deleterious in polycythemia vera, when in fact it is perfectly compatible with normal bone marrow function,134,155,181,183 is a reversible process,168,175,184-186 and has not been shown to impact adversely on survival.150,174,177 Indeed, failure to recognize polycythemia vera presenting as myelofibrosis is potentially more deleterious than the development of myelofibrosis during the course of the disease.

Phlebotomy and thrombosis

The most serious and damaging criticism of phlebotomy therapy in polycythemia vera is that it was associated with an excess of thrombotic events compared with other treatments.200Unfortunately, the data upon which this criticism is based were the consequence of a complete misunderstanding of the pathophysiology of erythrocytosis in polycythemia vera. In contrast to other forms of erythrocytosis in which expansion of the red cell mass is typically accompanied by a reduction in plasma volume, expansion of the plasma volume is common in polycythemia vera.110,132 That this was not initially appreciated was presumably due to the practice of measuring only the red cell mass.319 Plasma volume expansion is associated with a concomitant reduction in peripheral vascular resistance and an increased cardiac stroke volume for its accommodation. As a consequence, although peripheral vascular resistance eventually increases, it does so more slowly than when erythrocytosis occurs in a normovolemic setting and systemic oxygen transport is actually increased at any given hematocrit level.320 However, because of the plasma volume expansion, the hematocrit is no longer an accurate indicator of the red cell mass in polycythemia vera patients and this is particularly true when splenomegaly is present.130-132 Therefore, it is not surprising that PVSG data indicated that approximately 15% of patients with a hematocrit level of 50% and up to 40% with hematocrit levels of up to 55% had an elevated red cell mass88; similar observations have been made by others.321 More importantly, not only is cerebral blood flow impaired in polycythemia vera patients when the hematocrit level is more than 45%,267 but the incidence of thrombotic events shows a linear increase above the same hematocrit level.322 Thus, hematocrit values that are apparently within the normal range cannot be considered as safe in polycythemia vera patients and it is this syndrome of masked or inapparent erythrocytosis132 due to plasma volume expansion that is not only responsible for what has been termed a latent,323 “prethrombotic,”244or “forme fruste”324 myeloproliferative disorder but also the increased incidence of thrombotic events in such patients. Since even under normal circumstances, the hematocrit level in most organs with the exception of the spleen is much lower than the venous hematocrit level,124 it is clear that the situation in polycythemia vera is actually more serious than it appears and that the so-called “prethrombotic state” of polycythemia vera merely reflects inadequate reduction of the red cell mass.

The physiology of red cell mass expansion in polycythemia vera appeared to have been disregarded in the defining PVSG protocol-01, in which the phlebotomy treatment threshold was initially set at 50%,72 even though as indicated above, a minimum of 15% of male patients would be undertreated at this hematocrit level, as would 100% of women, since no woman normally has a hematocrit level of 50%. Unfortunately, even when the hematocrit threshold for phlebotomy was subsequently lowered to 45%,248 women patients were still at risk of undertreatment. Thus, the therapeutic conundrum of the PVSG, that treatment by phlebotomy alone resulted in a higher incidence of thrombosis during the first 3 years of therapy while chemotherapy or radiotherapy resulted in a high incidence of malignancy thereafter,243 was not a conundrum at all but rather the consequence of inadequate reduction of the red cell mass to begin with. Furthermore, since in polycythemia vera red cell production is tightly linked to the iron supply,325 differences in phlebotomy requirements were not a function of a difference in disease activity243 but rather in the extent of iron stores or availability. Unfortunately, based on a recent survey, an inappropriately high threshold for phlebotomy therapy is still being employed by many American hematologists.7 

Thrombocytosis and polycythemia vera: platelets at your finger tips

Fact versus fiction

Perhaps no other medical condition has caused more otherwise astute clinicians to abandon disbelief than thrombocytosis, particularly with respect to its contribution to the coagulopathy of polycythemia vera. The high frequency of vascular occlusion associated with this disease had been recognized for many years159but not until 1938, in the absence of any proof, was it suggested that thrombocytosis was a cause of major vessel thrombosis,146a suggestion subsequently accepted by influential clinicians145,154,290 without corroborating evidence. There is a particular irony in this since when essential thrombocytosis was first recognized, not only was it called hemorrhagic thrombocythemia326 but many of the patients described actually had unrecognized polycythemia vera.327,328 More importantly, no study to date, either prospective or retrospective, has demonstrated a correlation between platelet number or function and major vessel thrombosis. For example, in the PVSG prospective trial involving 431 patients, there was no correlation between an elevated platelet count and the risk of thrombosis,243 while a follow-up study employing antiplatelet agents failed to demonstrate a reduction in thrombotic events.329 This should not have been surprising considering the number of retrospective studies that failed to identify a correlation between the platelet count and risk of thrombosis,87,150,255,330,331 the well-established correlation of thrombosis with an elevated hematocrit level,322,331 and the failure of the PVSG to ensure adequate reduction of the red cell mass in their patients.72,200 Furthermore, even though a large number of platelet function abnormalities have been identified in polycythemia vera, they did not correlate with the development of thrombosis332 nor did age in some series.333Additionally, even when patients with isolated thrombocytosis were considered, it was difficult to incriminate the platelet count as a thrombotic risk factor. For example, most patients with familial thrombocytosis did not have an increased incidence of thrombosis334-338 nor did those with reactive thrombocytosis339 and in the only prospective, controlled study of essential thrombocytosis to date, the incidence of thrombosis in untreated patients was not greater than in the control population.340 

Part of the problem with defining the role of thrombocytosis as a thrombotic risk factor has been the intuition that it must be. This has led to reportorial bias with the publication and uncritical acceptance of anecdotal and incompletely studied case reports of unexpected thrombotic events occurring in association with thrombocytosis.242,341-343 These, unfortunately, not only fail to establish a cause and effect relationship but also merely provide a numerator without any denominator. As an example, when the factors associated with hepatic vein thrombosis were evaluated retrospectively, it was found that this event was actually preceded by a high hematocrit level and followed by thrombocytosis.249A second issue has been failure to consider other causes for hypercoagulability within the population under study such as the antiphospholipid syndrome344 or cardiovascular risk factors.345,346 In this regard, it is worth noting that the frequency of coronary artery thrombosis in the PVSG-01 trial243 was more in keeping with the latter than the frequency found by others for polycythemia vera patients in the absence of atherosclerotic disease.253 Indeed, when one considers the vaso-occlusive havoc initiated by heparin-induced thrombocytopenia or thrombotic thrombocytopenic purpura, it becomes immediately obvious that platelet number alone is not a critical determinant of hypercoagulability.

Hemorrhage and microvascular thrombosis

However, there is definitely a role for platelets in the coagulopathy that complicates polycythemia vera. With respect to bleeding, it has been established that platelet counts of more than 1 000 000/μL were associated with a hemorrhagic diathesis regardless of the cause.347,348 This was thought to be due to a reduction in high-molecular-weight von Willebrand multimers owing to their adsorption to platelets349 and was reversible with a reduction in platelet number350 or treatment with DDAVP.351 Equally important, and paradoxically, considering its effect on von Willebrand multimers, thrombocytosis can cause microvascular arteriolar thrombosis. This is manifest most often in peripheral vessels by the syndrome of erythromelalgia,352,353 and in the nervous system by a constellation of symptoms such as headache or ocular disturbances, often migrainous in type, amaurosis fugax, vertigo, diplopia, vertigo, hemiparesis, paresthesias, numbness, dysarthria, aphasia, and syncope.354 Usually transient and rarely progressive, these symptoms are distressing to patients and alarming to their physicians. Not infrequently, they may occur as the presenting manifestation of polycythemia vera and if superimposed on an already compromised vascular system could lead to a stroke, myocardial infarction, or peripheral gangrene.352,355 While the mechanism for platelet-associated microvascular occlusion is unknown, it is associated with increased platelet thromboxane B formation356 and increased platelet turnover.357,358 Both can be reversed or prevented by aspirin-induced platelet inactivation or a reduction in platelet count, though not necessarily to normal, suggesting that both platelet activation and platelet number are important. However, as demonstrated clinically,329 unless the red cell mass is appropriately reduced, antiplatelet therapy or chemotherapy will be futile, and this stipulation should be mandatory for any prospective study of the effect of antiplatelet therapy on large vessel thrombosis in polycythemia vera.

The management of polycythemia vera: first, do no harm

From the foregoing it is clear that the diagnosis and management of polycythemia vera continue to present formidable problems: polycythemia vera is a clonal disorder for which there is as yet no clinically validated clonal marker; trilineage hyperplasia is the hallmark of polycythemia vera but clinically the disease can mimic not only its companion myeloproliferative disorders, idiopathic myelofibrosis, and essential thrombocytosis, but also nonclonal causes of erythrocytosis; the disease is uncommon but its presenting manifestations are protean, ranging from intractable pruritus to the Budd-Chiari syndrome. Moreover, due to plasma volume expansion, splenomegaly, or hemorrhage, erythrocytosis, the one feature that sets polycythemia vera apart from the other chronic myeloproliferative disorders, may not be clinically obvious.132 Furthermore, contrary to conventional wisdom, the natural history of polycythemia vera has not been completely defined and neither staging criteria nor the factors affecting prognosis have been established even though it is well documented that the clinical course of the disorder is variable and that age and sex have an important influence in this regard.

While the currently accepted diagnostic criteria for polycythemia vera are useful for protocol studies, they do not define the limits of the disease, and a recent poll suggests considerable ambivalence among hematologists as to the optimal approach to the diagnosis of the disease as well as to its treatment.7 Remarkably, although erythrocytosis is the one feature that distinguishes polycythemia vera from its companion myeloproliferative disorders and the most frequent cause of serious complications, the utility of red cell mass and plasma volume determinations for diagnosis has been questioned as has the effectiveness of phlebotomy therapy. Unfortunately, the only prospective, controlled clinical trial of the disorder to date with respect to phlebotomy therapy, that of the PVSG, was flawed because the target hematocrit level chosen for phlebotomy therapy was too high.200 Thus, the therapeutic dilemma that patients treated initially with phlebotomy had an unacceptably high incidence of early thromboses while those treated with chemotherapy or32P later had a high incidence of leukemia, lymphoma, or cancer,243 is probably more apparent than real, at least with respect to the phlebotomy group. In the same fashion, given the lack of attention to reducing blood viscosity in this disorder, it can be seriously questioned whether a prior history of thrombosis and advanced age are truly risk factors for thrombosis in polycythemia vera patients.331 Certainly, neither chemotherapy nor radiotherapy has proved superior to phlebotomy in preventing thrombosis but both have proved to be more toxic.244 Furthermore, since polycythemia vera appears to be a myeloaccumulative disorder rather than a myeloproliferative one, at least with respect to the erythrocytosis and a disorder that is often indolent and of long duration, its treatment should be commensurate with that behavior.

The first issue with respect to management is diagnosis and it should be obvious that it is not possible to accurately estimate the red cell mass from the hematocrit level when polycythemia vera is a diagnostic consideration and the hematocrit level is less than 60% in a man or 50% in a woman. Measurement of the red cell mass and plasma volume by isotope dilution should be a standard of care but unfortunately this standard is more often honored in the breach than in the observance. In some locales, bogus medical economics have been allowed to dictate the availability of these procedures, which can only be seen as an abdication of our professional responsibilities as hematologists. While elevation of the red cell mass does not establish the diagnosis of polycythemia vera, the diagnosis cannot be made in its absence. Even if a clonal assay for polycythemia vera were available, such an assay would not abrogate the need for red cell mass and plasma volume determinations in this disease any more than the HFE assay for hemochromatosis has abrogated the need for serum transferrin saturation measurements as a guide to both diagnosis and therapy.

Reduction of the red cell mass and maintaining it at a safe level by phlebotomy (hematocrit level of < 45% in men and < 42% in women and < 36% during pregnancy) is the first principle of therapy in polycythemia vera. Venesection is a safe and immediately effective therapy and its desired side effect, iron deficiency, is not a liability,310 claims that cannot be made for any of the surrogate therapies for polycythemia vera that have been proposed to date. Reduction of the red cell mass and maintaining it at a physiologic level removes a major source of complications and may also alleviate systemic hypertension and pruritus359 and reduce splenomegaly.161,360 For many patients, no other therapy may be necessary for many years. Aspirin or anticoagulants such as coumadin are not substitutes for adequate phlebotomy; low doses of aspirin block urate excretion while titration of the coumadin dose can be difficult if the red cell mass is not controlled. Occasionally, with blood loss or overzealous phlebotomy, symptomatic anemia can ensue. Judicious iron replacement can accelerate the recovery process but too much iron will result in an explosive increase in red cell mass. The other complications of polycythemia vera (Table4), with the exception of leukemic transformation, represent the consequences of cell accumulation manifested as organ enlargement, microvascular occlusive or hemorrhagic phenomenon, hyperuricemia, or cytokine-mediated events such as pruritus and acid-peptic disease, but their treatment need not necessarily be genotoxic. For example, aspirin alone353,361 or anagrelide362 may be sufficient to combat the microvascular occlusive syndrome associated with thrombocytosis. It is, of course, important to remember that polycythemia vera patients are not immune to other illnesses causing thrombosis. Similarly, a modest leukocytosis requires no correction; however, if progressive, leukocytosis is a harbinger of extramedullary hematopoiesis or disease acceleration. In which case, the leukocytosis can serve as a guide to disease control following the institution of therapy.

Table 4.

The complications of polycythemia vera

Complication Cause 
Thrombosis, hypertension Elevated red cell mass 
Organomegaly Elevated red cell mass or extramedullary hematopoiesis  
Pruritis, acid-peptic disease Inflammatory mediators or elevated red cell mass  
Hyperuricemia, gout, renal stones Increased cell turnover  
Erythromelalgia or ocular migraine Thrombocytosis  
Hemorrhage Elevated red cell mass, or acquired von Willebrand disease due to thrombocytosis 
Myelofibrosis Reaction to the neoplastic clone  
Wasting syndrome Disease acceleration  
Acute leukemia Therapy-related or clonal evolution 
Complication Cause 
Thrombosis, hypertension Elevated red cell mass 
Organomegaly Elevated red cell mass or extramedullary hematopoiesis  
Pruritis, acid-peptic disease Inflammatory mediators or elevated red cell mass  
Hyperuricemia, gout, renal stones Increased cell turnover  
Erythromelalgia or ocular migraine Thrombocytosis  
Hemorrhage Elevated red cell mass, or acquired von Willebrand disease due to thrombocytosis 
Myelofibrosis Reaction to the neoplastic clone  
Wasting syndrome Disease acceleration  
Acute leukemia Therapy-related or clonal evolution 

Because there is currently no clonal marker for polycythemia vera, it is currently impossible to determine if a particular therapy is curative or merely palliative. In this regard, the long natural history of the disorder and the infrequent and unpredictable occurence of spontaneous leukemic transformation make it difficult to establish the superiority of any therapy or to recommend a potentially curative therapy such as allogeneic bone marrow transplantation that carries an immediate obligate mortality as well as the potential for substantial chronic morbidity. We are, however, fortunate to have a variety of symptomatic remedies for the many complications of polycythemia vera because no single remedy has proved completely effective for any of them. However, many of these remedies are not without risk and have their own unique toxicities. For example, pruritus can prove to be so intractable to phlebotomy, antihistamines, or psoralen-activated light therapy that resort must be made to suppression of hematopoiesis with alpha interferon, hydroxyurea, or even busulphan. Splenomegaly due to extramedullary hematopoiesis can be similarly difficult to manage. Yet attempts to avoid the complications of cell accumulation by chemotherapy or irradiation have not been without substantial toxicity,163,200,244 and while alpha interferon is a promising agent in this regard,363 it can have substantial side effects, particularly in the elderly364; it is also unknown whether this agent can alter the natural history of polycythemia vera. Tolerance to alpha interferon may be aided by starting with a low dose (500 000 U, 3 times per week) and escalating slowly; the addition of an antidepressant has also been found helpful.365 Although alpha interferon is expensive and its side effects can be debilitating, it has not been demonstrated to cause permanent marrow damage. The same may not be true for hydroxyurea,212,214,366 although the evidence is not entirely conclusive at this time. However, this was also the situation initially for other cytotoxic agents that subsequently proved to be leukemogenic in this disease. Therefore, it seems prudent to employ hydroxyurea only when other remedies have failed and to avoid long-term exposure whenever possible.

Since few physicians see many of these patients, the concerns described above emphasize the need to gain greater insight into the natural history of polycythemia vera and to reinitiate prospective, controlled multicenter clinical trials using the wisdom gained from such initiatives as the Cooperative Study of Sickle Cell Disease367 and the PVSG. Until such a time as those goals are realized, we can do no better than to heed the advice of William Dameshek, a proponent of phlebotomy therapy in polycythemia vera:There seems to be a tendency in medical practice—by no means limited to hematologists—to treat almost every condition as vigorously as possible. In hematology, this consists in attempting to change an abnormal number—whether this number is hemoglobin, hematocrit, WBC, platelet count to normal values whether the patient needs it or not!”238 

Prepublished online as Blood First Edition Paper, August 8, 2002; DOI 10.1182/blood-2001-12-0349.

References

References
1
Adamson
JW
Fialkow
PJ
Murphy
S
Prchal
JF
Steinmann
L
Polycythemia vera: stem-cell and probable clonal origin of the disease.
N Engl J Med.
295
1976
913
916
2
Adamson
JW
Singer
JW
Catalano
P
et al. 
Polycythemia vera: further in vitro studies of hematopoietic regulation.
J Clin Invest.
66
1980
1363
1368
3
Vaquez
H
Sur une Forme Speciale De Cyanose S'Accompagnant D' Hyperglobulie Excessive Et Peristante.
C R Soc Biol (Paris).
44
1892
384
388
4
Berglund
S
Zettervall
O
Incidence of polycythemia vera in a defined population.
Eur J Haematol.
48
1992
20
26
5
Ania
BJ
Suman
VJ
Sobell
JL
et al. 
Trends in the incidence of polycythemia vera among Olmsted County, Minnesota residents, 1935-1989.
Am J Hematol.
47
1994
89
93
6
McNally
RJ
Rowland
D
Roman
E
Cartwright
RA
Age and sex distributions of hematological malignancies in the UK.
Hematol Oncol.
15
1997
173
189
7
Streiff
MB
Smith
B
Spivak
JL
The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group.
Blood.
99
2002
1144
8
Berlin
NI
Lawrence
JH
Lee
HC
The life span of the red blood cell in chronic leukemia and polycythemia.
Science.
114
1951
385
387
9
Eaves
AC
Henkelman
DH
Eaves
CJ
Abnormal erythropoiesis in the myeloproliferative disorders: an analysis of underlying cellular and humoral mechanisms.
Exp Hematol.
8(suppl 8)
1980
235
247
10
Lawrence
JH
Elmlinger
PJ
Fulton
G
Oxygen and the control of red cell production in primary and secondary polycythemia: effects on iron turnover pattern with Fe59 as a tracer.
Cardiologia.
21
1952
337
346
11
Spivak
JL
Cooke
CR
Polycythemia vera in an anephric man.
Am J Med Sci.
272
1976
339
344
12
Falconer
E
Treatment of polycythemia: the reticulocyte response to venesection, phenylhydrazin and radiation.
Ann Intern Med.
7
1933
172
189
13
Stephens
DJ
Kaltreider
N
The therapeutic use of venesection in polycythemia.
Ann Intern Med.
10
1937
1565
1581
14
Carneskog
J
Kutti
J
Wadenvik
H
Lundberg
PA
Lindstedt
G
Plasma erythropoietin by high-detectability immunoradiometric assay in untreated and treated patients with polycythaemia vera and essential thrombocythaemia.
Eur J Haematol.
60
1998
278
282
15
Prchal
JF
Axelrad
AA
Bone marrow responses in polycythemia vera [letter].
N Engl J Med.
290
1974
1382
16
Golde
DW
Koeffler
HP
Adamson
JW
Polycythemia vera: mechanisms and management.
Ann Intern Med.
95
1981
71
87
17
Cashman
J
Henkelman
D
Humphries
K
Eaves
C
Eaves
A
Individual BFU-E in polycythemia vera produce both erythropoietin dependent and independent progeny.
Blood.
61
1983
876
884
18
Papayannopoulou
T
Buckley
J
Nakamoto
B
et al. 
Hb F production of endogenous colonies of polycythemia vera.
Blood.
53
1979
446
454
19
Eid
J
Ebert
RF
Gesell
MS
Spivak
JL
Intracellular growth factors in polycythemia vera and other myeloproliferative disorders.
Proc Natl Acad Sci U S A.
84
1987
532
536
20
de Wolf
JT
Beentjes
JA
Esselink
MT
et al. 
In polycythemia vera human interleukin 3 and granulocyte-macrophage colony-stimulating factor enhance erythroid colony growth in the absence of erythropoietin.
Exp Hematol.
17
1989
981
983
21
Dai
CH
Krantz
SB
Green
WF
Gilbert
HS
Polycythaemia vera. III. Burst-forming units-erythroid (BFU-E) response to stem cell factor and c-kit receptor expression.
Br J Haematol.
86
1994
12
21
22
Correa
PN
Eskinazi
D
Axelrad
AA
Circulating erythroid progenitors in polycythemia vera are hypersensitive to insulin-like growth factor-1 in vitro: studies in an improved serum-free medium.
Blood.
83
1994
99
112
23
Wickrema
A
Chen
F
Namin
F
et al. 
Defective expression of the SHP-1 phosphatase in polycythemia vera.
Exp Hematol.
27
1999
1124
1132
24
Dai
CH
Krantz
SB
Sawyer
ST
Polycythemia vera. V. Enhanced proliferation and phosphorylation due to vanadate are diminished in polycythemia vera erythroid progenitor cells: a possible defect of phosphatase activity in polycythemia vera.
Blood.
89
1997
3574
3581
25
Andersson
P
LeBlanc
K
Eriksson
BA
Samuelsson
J
No evidence for an altered mRNA expression or protein level of haematopoietic cell phosphatase in CD34+ bone marrow progenitor cells or mature peripheral blood cells in polycythaemia vera.
Eur J Haematol.
59
1997
310
317
26
Asimakopoulos
FA
Hinshelwood
S
Gilbert
JG
et al. 
The gene encoding hematopoietic cell phosphatase (SHP-1) is structurally and transcriptionally intact in polycythemia vera.
Oncogene.
14
1997
1215
1222
27
Sui
X
Krantz
S
Zhao
Z
Identification of increased protein tyrosine phosphatase activity in polycythemia vera erythroid progenitor cells.
Blood.
90
1997
651
657
28
Dai
C
Krantz
SB
Increased expression of the INK4a/ARF locus in polycythemia vera.
Blood.
97
2001
3424
3432
29
Roder
S
Steimle
C
Meinhardt
G
Pahl
HL
STAT3 is constitutively active in some patients with polycythemia rubra vera.
Exp Hematol.
29
2001
694
702
30
Gaidano
G
Guerrasio
A
Serra
A
et al. 
Mutations in the P53 and RAS family genes are associated with tumor progression of BCR/ABL negative chronic myeloproliferative disorders.
Leukemia.
7
1993
946
953
31
Chen
Z
Notohamiprodjo
M
Guan
XY
et al. 
Gain of 9p in the pathogenesis of polycythemia vera.
Genes Chromosomes Cancer.
22
1998
321
324
32
Najfeld
V
Montella
L
Scalise
A
Fruchtman
SM
Exploring polycythemia vera with FISH: additional cryptic 9p is the most frequent abnormality detected.
Br J Haematol.
119
2002
1
9
33
Nunez
C
Bashein
AM
Brunet
CL
et al. 
Expression of the imprinted tumour-suppressor gene H19 is tightly regulated during normal haematopoiesis and is reduced in haematopoietic precursors of patients with the myeloproliferative disease polycythaemia vera.
J Pathol.
190
2000
61
68
34
Kralovics
R
Guan
Y
Prchal
JT
Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera.
Exp Hematol.
30
2002
229
236
35
Dai
CH
Krantz
SB
Koury
ST
Kollar
K
Polycythemia vera. IV. Specific binding of stem cell factor to normal and polycythemia vera highly purified erythroid progenitor cells.
Br J Haematol.
88
1994
497
505
36
Yoshimura
A
Longmore
G
Lodish
HF
Point mutation in the exoplasmic domain of the erythropoietin receptor resulting in hormone-independent activation and tumorigenicity.
Nature.
348
1990
647
649
37
Means
RT
Krantz
SB
Gilbert
HS
Erythropoietin receptors in polycythemia vera.
J Clin Invest.
84
1989
1340
1344
38
Broudy
VC
Kin
N
Papayannopoulou
T
Erythropoietin receptors in polycythemia vera.
Exp Hematol.
18
1990
576a
39
Hess
G
Rose
P
Gamm
H
et al. 
Molecular analysis of the erythropoietin receptor system in patients with polycythaemia vera.
Br J Haematol.
88
1994
794
802
40
Lu
L
Ge
Y
Li
ZH
et al. 
Retroviral transfer of the recombinant human erythropoietin receptor gene into single hematopoietic stem/progenitor cells from human cord blood increases the number of erythropoietin-dependent erythroid colonies.
Blood.
87
1996
525
534
41
Longmore
GD
Pharr
P
Neumann
D
Lodish
HF
Both megakaryocytopoiesis and erythropoiesis are induced in mice infected with a retrovirus expressing an oncogenic erythropoietin receptor.
Blood.
82
1993
2386
2395
42
Nakamura
Y
Komatsu
N
Nakauchi
H
A truncated erythropoietin receptor that fails to prevent programmed cell death of erythroid cells.
Science.
257
1992
1138
1141
43
Schwall
R
A truncated erythropoietin receptor and cell death.
Science.
259
1993
696
44
Nakamura
Y
Nakauchi
H
A truncated erythropoietin receptor and cell death: a reanalysis.
Science.
264
1994
588
589
45
Nakamura
Y
Tokumoto
Y
Nakauchi
H
Role of a truncated erythropoietin receptor for erythroid differentiation.
Biochem Biophys Res Commun.
218
1996
205
209
46
Chiba
S
Takahashi
T
Takashita
K
et al. 
Selective expression of mRNA coding for the truncated form of erythropoietin receptor in hematopoietic cells and its decrease in patients with polycythemia vera.
Blood.
90
1997
97
104
47
Silva
M
Richard
C
Benito
A
et al. 
Expression of Bcl-x in erythroid precursors from patients with polycythemia vera.
N Engl J Med.
338
1998
564
571
48
Spivak
JL
Pham
T
Isaacs
M
Hankins
WD
Erythropoietin is both a mitogen and a survival factor.
Blood.
77
1991
1228
1233
49
Koury
MJ
Bondurant
MC
Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells.
Science.
248
1990
378
381
50
Spivak
JL
Ferris
DK
Fisher
J
et al. 
Cell cycle-specific behavior of erythropoietin.
Exp Hematol.
24
1996
141
150
51
Silva
M
Grillot
D
Benito
A
et al. 
Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2.
Blood.
88
1996
1576
1582
52
Fairbairn
LJ
Cowling
GJ
Reipert
BM
Dexter
TM
Suppression of apoptosis allows differentiation and development of a multipotent hemopoietic cell line in the absence of added growth factors.
Cell.
74
1993
823
832
53
Carroll
M
Zhu
Y
D'Andrea
AD
Erythropoietin-induced cellular differentiation requires prolongation of the G1 phase of the cell cycle.
Proc Natl Acad Sci U S A.
92
1995
2869
2873
54
Gregoli
PA
Bondurant
MC
The roles of Bcl-X(L) and apopain in the control of erythropoiesis by erythropoietin.
Blood.
90
1997
630
640
55
Mirza
AM
Correa
PN
Axelrad
AA
Increased basal and induced tyrosine phosphorylation of the insulin-like growth factor I receptor beta subunit in circulating mononuclear cells of patients with polycythemia vera.
Blood.
86
1995
877
882
56
Mirza
AM
Ezzat
S
Axelrad
AA
Insulin-like growth factor binding protein-1 is elevated in patients with polycythemia vera and stimulates erythroid burst formation in vitro.
Blood.
89
1997
1862
1869
57
Damen
JE
Krosl
J
Morrison
D
Pelech
S
Krystal
G
The hyperresponsiveness of cells expressing truncated erythropoietin receptors is contingent on insulin-like growth factor-1 in fetal calf serum.
Blood.
92
1998
425
433
58
Solar
GP
Kerr
WG
Zeigler
FC
et al. 
Role of c-mpl in early hematopoiesis.
Blood.
92
1998
4
10
59
Borge
OJ
Ramsfjell
V
Cui
L
Jacobsen
SE
Ability of early acting cytokines to directly promote survival and suppress apoptosis of human primitive CD34+.
Blood.
90
1997
2282
2292
60
Young
JC
Bruno
E
Luens
KM
et al. 
Thrombopoietin stimulates megakaryocytopoiesis, myelopoiesis, and expansion of CD34+ progenitor cells from single CD34+Thy-1+Lin- primitive progenitor cells.
Blood.
88
1996
1619
1631
61
Carver-Moore
K
Broxmeyer
HE
Luoh
SM
et al. 
Low levels of erythroid and myeloid progenitors in thrombopoietin-and c-mpl-deficient mice.
Blood.
88
1996
803
808
62
Sawai
N
Koike
K
Ito
S
et al. 
Neutrophilic cell production by combination of stem cell factor and thrombopoietin from CD34(+) cord blood cells in long-term serum-deprived liquid culture.
Blood.
93
1999
509
518
63
Papayannopoulou
T
Brice
M
Farrer
D
Kaushansky
K
Insights into the cellular mechanisms of erythropoietin-thrombopoietin synergy.
Exp Hematol.
24
1996
660
669
64
Ratajczak
MZ
Ratajczak
J
Marlicz
W
et al. 
Recombinant human thrombopoietin (TPO) stimulates erythropoiesis by inhibiting erythroid progenitor cell apoptosis.
Br J Haematol.
98
1997
8
17
65
Villeval
JL
Cohen-Solal
K
Tulliez
M
et al. 
High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice.
Blood.
90
1997
4369
4383
66
Cocault
L
Bouscary
D
Le Bousse Kerdiles
MC
et al. 
Ectopic expression of murine TPO receptor (c-mpl) in mice is pathogenic and induces erythroblastic proliferation.
Blood.
88
1996
1656
1665
67
Wendling
F
Varlet
P
Charon
M
Tambourin
P
MPLV: a retrovirus complex inducing an acute myeloproliferative leukemic disorder in adult mice.
Virology.
149
1986
242
246
68
Souyri
M
Vigon
I
Penciolelli
JF
et al. 
A putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalizes hematopoietic progenitors.
Cell.
63
1990
1137
1147
69
Moliterno
AR
Spivak
JL
Posttranslational processing of the thrombopoietin receptor is impaired in polycythemia vera.
Blood.
94
1999
2555
2561
70
Sabath
DF
Kaushansky
K
Broudy
VC
Deletion of the extracellular membrane-distal cytokine receptor homology module of Mpl results in constitutive cell growth and loss of thrombopoietin binding.
Blood.
94
1999
365
367
71
Osler
W
Chronic cyanosis, with polycythemia and enlarged spleen: a new clinical entity.
Am J Med Sci.
126
1903
176
201
72
Wasserman
L
The management of polycythemia vera.
Br J Haematol.
21
1971
371
376
73
Ellis
JT
Silver
RT
Coleman
M
Geller
SA
The bone marrow in polycythemia vera.
Semin Hematol.
12
1975
433
444
74
Swolin
B
Weinfeld
A
Westin
J
A prospective long-term cytogenetic study in polycythemia vera in relation to treatment and clinical course.
Blood.
72
1988
386
395
75
Ellis
JT
Peterson
P
Geller
SA
Rappaport
H
Studies of the bone marrow in polycythemia vera and the evolution of myelofibrosis and second hematologic malignancies.
Semin Hematol.
23
1986
144
155
76
Kilbridge
TM
Fried
W
Heller
P
The mechanism by which plethora suppresses erythropoiesis.
Blood.
33
1969
104
113
77
Cazzola
M
Guarnone
R
Cerani
P
et al. 
Red blood cell precursor mass as an independent determinant of serum erythropoietin level.
Blood.
91
1998
2139
2145
78
Haga
P
Cotes
PM
Till
JA
Minty
BD
Shinebourne
EA
Serum immunoreactive erythropoietin in children with cyanotic and acyanotic congenital heart disease.
Blood.
70
1987
822
826
79
Dudley
JM
Westwood
N
Leonard
S
Eridani
S
Pearson
TC
Primary polycythaemia: positive diagnosis using the differential response of primitive and mature erythroid progenitors to erythropoietin, interleukin 3 and alpha-interferon.
Br J Haematol.
75
1990
188
194
80
Dainiak
N
Hoffman
R
Lebowitz
AI
et al. 
Erythropoietin-dependent primary pure erythrocytosis.
Blood.
53
1979
1076
1084
81
Eridani
S
Dudley
JM
Sawyer
BM
Pearson
TC
Erythropoietic colonies in a serum-free system: results in primary proliferative polycythaemia and thrombocythaemia.
Br J Haematol.
67
1987
387
391
82
Turhan
AG
Cashman
JD
Eaves
CJ
Humphries
RK
Eaves
AC
Variable expression of features of normal and neoplastic stem cells in patients with thrombocytosis.
Br J Haematol.
82
1992
50
57
83
Juvonen
E
Ikkala
E
Oksanen
K
Ruutu
T
Megakaryocyte and erythroid colony formation in essential thrombocythaemia and reactive thrombocytosis: diagnostic value and correlation to complications.
Br J Haematol.
83
1993
192
197
84
Ciaudo
M
Hadjez
JM
Teyssandier
I
et al. 
Prognostic and diagnostic value of endogenous erythroid colony formation in essential thrombocythemia.
Hematol Cell Ther.
40
1998
171
174
85
Lemoine
F
Najman
A
Baillou
C
et al. 
A prospective study of the value of bone marrow erythroid progenitor cultures in polycythemia.
Blood.
68
1986
996
1002
86
Weinberg
RS
Worsley
A
Gilbert
HS
et al. 
Comparison of erythroid progenitor cell growth in vitro in polycythemia vera and chronic myelogenous leukemia: only polycythemia vera has endogenous colonies.
Leuk Res.
13
1989
331
338
87
Szur
L
Lewis
SM
Goolden
AWG
Polycythemia vera and its treatment with radioactive phosphorus.
Q J Med.
28
1959
397
424
88
Berlin
NI
Diagnosis and classification of the polycythemias.
Semin Hematol.
12
1975
339
351
89
Temerinac
S
Klippel
S
Strunck
E
et al. 
Cloning of PVR-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera.
Blood.
95
2000
2569
2579
90
Bessman
DJ
Microcytic polycythemia: frequency of nonthalassemic causes.
JAMA.
238
1977
2391
2392
91
Gilbert
HS
Goldberg
R
Ward
L
Increased circulating neutrophils with surface receptor activity for immunoglobulin G in polycythemia vera and myeloid metaplasia.
Blood.
53
1979
1106
1113
92
Samuelsson
J
Forslid
J
Hed
J
Palmblad
J
Studies of neutrophil and monocyte oxidative responses in polycythaemia vera and related myeloproliferative disorders.
Br J Haematol.
87
1994
464
470
93
Cooper
B
Ahern
D
Characterization of the platelet prostaglandin D2 receptor: loss of prostaglandin D2 receptors in platelets of patients with myeloproliferative disorders.
J Clin Invest.
64
1979
586
590
94
Okuma
M
Uchino
H
Altered arachidonate metabolism by platelets in patients with myeloproliferative disorders.
Blood.
54
1979
1258
1271
95
Schafer
AI
Deficiency of platelet lipoxygenase activity in myeloproliferative disorders.
N Engl J Med.
306
1982
381
386
96
Moliterno
AR
Hankins
WD
Spivak
JL
Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera.
N Engl J Med.
338
1998
572
580
97
Horikawa
Y
Matsumura
I
Hashimoto
K
et al. 
Markedly reduced expression of platelet c-mpl receptor in essential thrombocythemia.
Blood.
90
1997
4031
4038
98
Moliterno
AR
Silver
RT
Spivak
JL
A diagnostic assay for polycythemia vera.
Blood.
96
2001
512a
99
Yoon
SY
Li
CY
Tefferi
A
Megakaryocyte c-Mpl expression in chronic myeloproliferative disorders and the myelodysplastic syndrome: immunoperoxidase staining patterns and clinical correlates.
Eur J Haematol.
65
2000
170
174
100
Klippel
S
Strunck
E
Temerinac
S
et al. 
Quantification of PRV-1 expression, a molecular marker for the diagnosis of polycythemia vera.
Blood.
98
2001
470a
101
Diez-Martin
JL
Graham
DL
Petitt
RM
Dewald
GW
Chromosome studies in 104 patients with polycythemia vera.
Mayo Clin Proc.
66
1991
287
299
102
Rege-Cambrin
G
Mecucci
C
Tricot
G
et al. 
A chromosomal profile of polycythemia vera.
Cancer Genet Cytogenet.
25
1987
233
245
103
el Kassar
N
Hetet
G
Briere
J
Grandchamp
B
Clonality analysis of hematopoiesis in essential thrombocythemia: advantages of studying T lymphocytes and platelets.
Blood.
89
1997
128
134
104
Busque
L
Mio
R
Mattioli
J
et al. 
Nonrandom X-inactivation patterns in normal females: lyonization ratios vary with age.
Blood.
88
1996
59
65
105
Gale
RE
Fielding
AK
Harrison
CN
Linch
DC
Acquired skewing of X-chromosome inactivation patterns in myeloid cells of the elderly suggests stochastic clonal loss with age.
Br J Haematol.
98
1997
512
519
106
Gilbert
HL
Acharya
J
Pearson
TC
Implications for the use of X-chromosome inactivation patterns and their relevance to the myeloproliferative disorders.
Eur J Haematol.
61
1998
282
283
107
Prchal
JT
Sokol
L
“Benign erythrocytosis” and other familial and congenital polycythemias.
Eur J Haematol.
57
1996
263
268
108
Ang
SO
Chen
H
Gordeuk
VR
et al. 
Endemic polycythemia in Russia: mutation in the VHL gene.
Blood Cells Mol Dis.
28
2002
57
62
109
Blum
A
Zbar
M
Relative polycythemia.
Arch Intern Med.
104
1959
385
389
110
Watts
EJ
Lewis
SM
Spurious polycythaemia—a study of 35 patients.
Scand J Haematol.
31
1983
241
247
111
Berlin
NI
Lewis
SM
Measurement of total RBC volume relative to lean body mass for diagnosis of polycythemia.
Am J Clin Pathol.
114
2000
922
926
112
Spivak
JL
The clinical physiology of erythropoietin.
Semin Hematol.
30
1993
2
11
113
Verel
D
Blood volume changes in cyanotic congenital heart disease and polycythemia rubra vera.
Circulation.
23
1961
749
753
114
Weil
JV
Jamieson
G
Brown
DW
et al. 
The red cell mass-arterial oxygen relationship in normal man.
J Clin Invest.
47
1968
1627
1639
115
Smith
JR
Landaw
SA
Smokers' polycythemia.
N Engl J Med.
298
1978
972
973
116
Sanchez
C
Merino
C
Figallo
M
Simultaneous measurement of plasma volume and cell mass in polycythemia of high altitude.
J Appl Physiol.
28
1970
775
778
117
Lim
VS
DeGowin
RL
Zavala
D
et al. 
Recombinant human erythropoietin treatment in pre-dialysis patients: a double-blind placebo-controlled trial.
Ann Intern Med.
110
1989
108
114
118
Besa
EC
Gorshein
D
Gardner
FH
Androgens and human blood volume changes: comparison in normal and various anemic states.
Arch Intern Med.
133
1974
418
425
119
Sawka
MN
Dennis
RC
Gonzalez
RR
et al. 
Influence of polycythemia on blood volume and thermoregulation during exercise-heat stress.
J Appl Physiol.
62
1987
912
918
120
Singh
A
Eckardt
KU
Zimmermann
A
et al. 
Increased plasma viscosity as a reason for inappropriate erythropoietin formation.
J Clin Invest.
91
1993
251
256
121
Murray JF. Arterial studies in primary and secondary polycythemic disorders. J Clin Invest. 1964;435-449.
122
Campbell
A
Emery
EW
Godlee
JN
Prankerd
TAJ
Diagnosis and treatment of primary polcy-thaemia.
Lancet.
1
1970
1074
1077
123
Smith
HP
Arnold
HR
Whipple
GH
Comparative values of Welcker, carbon monoxide and dye methods for blood volume determinations. accurate estimation of absolute blood volume.
Am J Physiol.
56
1921
336
360
124
Gibson
JG
Seligman
A
Peacock
WC
et al. 
The distribution of red cells and plasma in large and minute vessels of the normal dog, determined by radioactive isotopes of iron and iodine.
J Clin Invest.
5
1946
848
857
125
Ebert
R
Stead
EA
Demonstration that the cell plasma ratio of blood contained in minute vessels is lower than that of venous blood.
J Clin Invest.
20
1941
317
321
126
Berson
S
Yalow
RS
The use of K42 or P32 labeled erythrocytes and I131 tagged human serum albumin in simultaneous blood volume determinations.
J Clin Invest.
31
1952
572
580
127
Retzlaff
JA
Tauxe
WN
Kiely
JM
Stroebel
CF
Erythrocyte volume, plasma volume, and lean body mass in adult men and women.
Blood.
33
1969
649
661
128
Fahraeus
R
Lindqvuist
T
The viscosity of the blood in narrow capillary tubes.
Am J Physiol.
96
1931
562
568
129
Jonsson
V
Bock
JE
Nielsen
JB
Significance of plasma skimming and plasma volume expansion.
J Appl Physiol.
72
1992
2047
2051
130
Huber
H
Lewis
SM
Szur
L
The influence of anaemia, polycythaemia and splenomegaly on the relationship between venous haematocrit and red-cell volume.
Br J Haematol.
10
1964
567
575
131
Zhang
B
Lewis
SM
The splenomegaly of myeloproliferative disorders: effects on blood volume and red blood count.
Eur J Haematol.
42
1989
250
253
132
Lamy
T
Devillers
A
Bernard
M
et al. 
Inapparent polycythemia vera: an unrecognized diagnosis.
Am J Med.
102
1997
14
20
133
Lawrence
JH
Berlin
NI
Huff
RL
The nature and treatment of polycythemia.
Medicine.
32
1953
323
388
134
Barosi
G
Cazzola
M
Frassoni
F
Orlandi
E
Stefanelli
M
Erythropoiesis in myelofibrosis with myeloid metaplasia: recognition of different classes of patients by erythrokinetics.
Br J Haematol.
48
1981
263
272
135
Pettit
JE
Lewis
SM
Nicholas
AW
Transitional myeloproliferative disorder.
Br J Haematol.
43
1979
167
184
136
Najean
Y
Arrago
JP
Rain
JD
Dresch
C
The ‘spent’ phase of polycythaemia vera: hypersplenism in the absence of myelofibrosis.
Br J Haematol.
56
1984
163
170
137
Stead
EA
Ebert
RF
Relationship of the plasma volume and the cell plasma ratio to the total red cell volume.
Am J Physiol.
132
1941
411
417
138
Strumia
MM
Strumia
PV
Dugan
A
Significance of measurement of plasma volume and of indirect estimation of red cell volume.
Transfusion.
8
1968
197
209
139
Pearson
TC
Guthrie
DL
Simpson
J
et al. 
Interpretation of measured red cell mass and plasma volume in adults: expert panel on radionuclides of the International Council for Standardization in Haematology.
Br J Haematol.
89
1995
748
756
140
Pearson
TC
Glass
UH
Wetherley-Mein
G
Interpretation of measured red cell mass in the diagnosis of polycythaemia.
Scand J Haematol.
21
1978
153
162
141
Fairbanks
VF
Klee
GG
Wiseman
GA
et al. 
Measurement of blood volume and red cell mass: re-examination of 51Cr and 125I methods.
Blood Cells Mol Dis.
22
1996
169
186
142
Fairbanks
V
Polycythemia vera: the packed cell volume and the curious logic of the red cell mass.
Hematology.
4
2000
381
395
143
Fairbanks
VF
Tefferi
A
Normal ranges for packed cell volume and hemoglobin concentration in adults: relevance to ‘apparent polycythemia.’
Eur J Haematol.
65
2000
285
296
144
Hess
CH
Ayers
CR
Sandusky
WR
et al. 
Mechanism of dilutional anemia in massive splenomegaly.
Blood.
47
1976
629
644
145
Wasserman
LR
Polycythemia vera—its course and treatment relation to myeloid metaplasia and leukemia.
Bull N Y Acad Med.
30
1954
343
375
146
Rosenthal
N
Bassen
F
Course of polycythemia.
Arch Int Med.
62
1938
903
917
147
Minot
G
Buckman
TE
Erythremia (polycythemia vera): the development of anemia; the relation to leukemia; consideration of the basal metabolism, blood formation and destruction and fragility of the red cells.
Am J Med Sci.
166
1923
469
488
148
Dameshek
W
Physiopathology and course of polycythemia vera as related to therapy.
JAMA.
142
1950
790
797
149
Perkins
J
Israels
MCG
Wilkinson
JF
Polycythemia vera: clinical studies on a series of 127 patients managed without radiation therapy.
Q J Med.
33
1964
499
518
150
Messinezy
M
Pearson
TC
Prochazka
A
Wetherley-Mein
G
Treatment of primary proliferative polycythaemia by venesection and low dose busulphan: retrospective study from one centre.
Br J Haematol.
61
1985
657
666
151
Najean
Y
Mugnier
P
Dresch
C
Rain
JD
Polycythaemia vera in young people: an analysis of 58 cases diagnosed before 40 years.
Br J Haematol.
67
1987
285
291
152
Dameshek
W
Some speculations on the myeloproliferative syndromes.
Blood.
6
1951
372
375
153
Glasser
RM
Walker
RI
Transitions among the myeloproliferative disorders.
Ann Intern Med.
71
1969
285
307
154
Moschcowitz
E
Essays on the biology of disease.
J Mt Sinai Hosp.
6
1944
232
235
155
Pollycove
M
Winchell
HS
Lawrence
JH
Classification and evolution of patterns of erythropoiesis in polycythemia vera as studied by iron kinetics.
Blood.
28
1966
807
829
156
Chievitz
E
Thiede
T
Complications and causes of death in polycythemia vera.
Acta Med Scand.
172
1962
513
523
157
Silverstein
MN
The evolution into and the treatment of late stage polycythemia vera.
Semin Hematol.
13
1976
79
84
158
Roberts
BE
Miles
DW
Woods
CG
Polycy-thaemia vera and myelosclerosis: a bone marrow study.
Br J Haematol.
16
1969
75
85
159
Harrop
G
Polycythemia.
Medicine.
7
1928
291
344
160
Tinney
WS
Hall
BE
Giiffin
HZ
The liver and spleen in polycythemia vera.
Proc Staff Meetings Mayo Clin.
18
1943
46
47
161
Hines
L
Darnall
W
The control of polycythemia vera by venesection.
Ann J Med Sci.
206
1943
434
435
162
Pettit
JE
Lewis
SM
Williams
ED
et al. 
Quantitative studies of splenic erythropoiesis in polycythaemia vera and myelofibrosis.
Br J Haematol.
34
1976
465
475
163
Modan
B
Lilienfeld
AM
Polycythemia vera and leukemia—the role of radiation treatment.
Medicine.
44
1965
305
339
164
Silverstein
MN
Postpolycythemia myeloid metaplasia.
Arch Intern Med.
134
1974
113
117
165
Kurnick
JE
Mahmood
T
Napoli
N
Block
MH
Extension of myeloid tissue into the lower extremities in polycythemia.
Am J Clin Pathol.
74
1980
427
431
166
Rigby
PG
Leavell
BS
Polycythemia vera.
Arch Intern Med.
5
1960
100
105
167
Tubiana
M
Flamant
R
Attie
E
Hayat
M
A study of hematological complications occurring in patients with polycythemia vera treated with 32-P (based on a series of 296 patients).
Blood.
32
1968
536
548
168
Wolf
BC
Neiman
RS
Myelofibrosis with myeloid metaplasia: pathophysiologic implications of the correlation between bone marrow changes and progression of splenomegaly.
Blood.
65
1985
803
809
169
Najean
Y
Rain
J
Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years.
Blood.
90
1997
3370
3377
170
Rameshwar
P
Chang
VT
Thacker
UF
Gascon
P
Systemic transforming growth factor-beta in patients with bone marrow fibrosis—pathophysiological implications.
Am J Hematol.
59
1998
133
142
171
Johnston
JB
Dalal
BI
Israels
SJ
et al. 
Deposition of transforming growth factor-beta in the marrow in myelofibrosis, and the intracellular localization and secretion of TGF-beta by leukemic cells.
Am J Clin Pathol.
103
1995
574
582
172
Frey
BM
Rafii
S
Teterson
M
et al. 
Adenovector-mediated expression of human thrombopoietin cDNA in immune-compromised mice: insights into the pathophysiology of osteomyelofibrosis.
J Immunol.
160
1998
691
699
173
Leonard
BJ
Israels
MCG
Wilkinson
JF
Myelosclerosis: a clinicopathological study.
Q J Med.
26
1957
131
149
174
Pereira
A
Cervantes
F
Brugues
R
Rozman
C
Bone marrow histopathology in primary myelofibrosis: clinical and haematologic correlations and prognostic evaluation.
Eur J Haematol.
44
1990
95
99
175
Korst
D
Clatanoff
DV
Schilling
RF
On myelofibrosis.
Arch Intern Med.
97
1955
169
183
176
Najean
Y
Dresch
C
Rain
JD
The very-long-term course of polycythaemia: a complement to the previously published data of the Polycythaemia Vera Study Group [see comments].
Br J Haematol.
86
1994
233
235
177
Pitcock
JA
Reinhard
EH
Justus
BW
Mendelsohn
RS
A clinical and pathological study of seventy cases of myelofibrosis.
Ann Intern Med.
57
1962
73
84
178
Barosi
G
Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines.
J Clin Oncol.
17
1999
2954
2970
179
Burston
J
Pinniger
JL
The reticulin content of bone marrow in haematological disorders.
Br J Haematol.
9
1963
172
184
180
Najean
Y
Deschamps
A
Dresch
C
et al. 
Acute leukemia and myelodysplasia in polycythemia vera: a clinical study with long-term follow-up.
Cancer.
61
1988
89
95
181
Ikkala
E
Rapola
J
Kotilainen
M
Polycythaemia vera and myelofibrosis.
Scand J Haemat.
4
1967
453
464
182
Kreft
A
Nolde
C
Busche
G
et al. 
Polycythaemia vera: bone marrow histopathology under treatment with interferon, hydroxyurea and busulphan.
Eur J Haematol.
64
2000
32
41
183
Najean
Y
Cacchione
R
Castro-Malaspina
H
Dresch
C
Erythrokinetic studies in myelofibrosis: their significance for prognosis.
Br J Haematol.
40
1978
205
217
184
Manoharan
A
Pitney
WR
Chemotherapy resolves symptoms and reverses marrow fibrosis in myelofibrosis.
Scand J Haematol.
33
1984
453
459
185
Pettit
JE
Lewis
SM
Goolden
AWG
Polycythemia vera: transformation to myelofibrosis and subsequent reversal.
Scand J Haematol.
20
1978
63
69
186
Pamphilon
DH
Creamer
P
Keeling
DH
Prentice
AG
Restoration of active haemopoiesis in a patient with myelofibrosis and subsequent termination in acute myeloblastic leukaemia: case report and review of the literature.
Eur J Haematol.
38
1987
279
283
187
Lohmann
TP
Beckman
EN
Progressive myelofibrosis in agnogenic myeloid metaplasia.
Arch Pathol Lab Med.
107
1983
593
594
188
Hasselbalch
H
Lisse
I
A sequential histological study of bone marrow fibrosis in idiopathic myelofibrosis.
Eur J Haematol.
46
1991
285
289
189
Szur
L
Lewis
SM
The haematological complications of polycythaemia vera and treatment with radioactive phosphorus.
Br J Radiol.
39
1966
122
130
190
Bouroncle
B
Doan
CA
Myelofibrosis: clinical, hematologic and pathologic study of 110 patients.
Am J Med Sci.
243
1962
697
715
191
Linman
J
Bethell
F
Agnogenic myeloid metaplasia.
Am J Med.
22
1957
107
122
192
Hoffbrand
AV
Chanarin
I
Kremenchuzky
S
et al. 
Megaloblastic anaemia in myelosclerosis.
Q J Med.
37
1968
493
514
193
Silverstein
MN
Brown
AL
Linman
J
Idiopathic myeloid metaplasia: its evolution into acute leukemia.
Arch Intern Med.
132
1973
709
712
194
Anger
B
Haug
U
Seidler
R
Heimpel
H
Polycythemia vera: a clinical study of 141 patients.
Blut.
59
1989
493
500
195
Haanen
C
Mathe
G
Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial.
Br J Cancer.
44
1981
75
80
196
Lazzarino
M
Morra
E
Castello
A
et al. 
Myelofibrosis in chronic granulocytic leukaemia: clinicopathologic correlations and prognostic significance.
Br J Haematol.
64
1986
227
240
197
Schwartz
SO
Ehrlich
L
The relationship of polycythemia vera to leukemia: a critical review.
Acta Med Scand.
4
1950
129
147
198
Osgood
EE
Contrasting incidence of acute monocytic and granulocytic leukemias in P32-treated patients with polycythemia vera and chronic lymphocytic leukemia.
J Lab Clin Med.
64
1964
560
573
199
Halnan
KE
Russell
MH
Comparison of survival and causes of death in patients managed with and without radiotherapy.
Lancet.
1
1965
760
763
200
Berk
PD
Goldberg
JD
Silverstein
MN
et al. 
Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy.
N Engl J Med.
304
1981
441
447
201
Brandt
L
Anderson
H
Survival and risk of leukaemia in polycythaemia vera and essential thrombocythaemia treated with oral radiophosphorus: are safer drugs available?
Eur J Haematol.
54
1995
21
26
202
Smith
PG
Doll
R
Mortality among patients with ankylosing spondylitis after a single treatment course with x rays.
Br Med J.
284
1982
449
460
203
Simpson
CL
Hempelmann
LH
Fuller
LM
Neoplasia in children treated with x-rays in infancy for thymic enlargement.
Radiology.
64
1955
840
845
204
Lawrence
JH
The control of polycythemia by marrow inhibition.
JAMA.
141
1949
13
18
205
Rosner
F
Acute leukemia as a delayed consequence of cancer chemotherapy.
Cancer.
37
1976
1033
1036
206
Reimer
RR
Hoover
R
Fraumeni
JF
Young
RC
Acute leukemia after alkylating-agent therapy of ovarian cancer.
N Engl J Med.
297
1977
177
181
207
Weinfeld
A
Westin
J
Ridell
B
Swolin
B
Polycythaemia vera terminating in acute leukaemia: a clinical, cytogenetic and morphologic study in 8 patients treated with alkylating agents.
Scand J Haematol.
19
1977
255
272
208
Michels
S
McKenna
RW
Arthur
DC
Brunning
RD
Therapy-related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphologic study of 65 cases.
Blood.
65
1985
1364
1372
209
Lawrence
JH
Winchell
HS
Donald
WG
Leukemia in polycythemia vera: relationship to splenic myeloid metaplasia and therapeutic radiation dose.
Ann Intern Med.
70
1969
763
771
210
Modan
B
Modan
M
Benign erythrocytosis.
Br J Haematol.
14
1968
375
381
211
Najean
Y
Triebel
F
Dresch
C
Pure erythrocytosis: reappraisal of a study of 51 cases.
Am J Hematol.
10
1981
129
136
212
Weinfeld
A
Swolin
B
Westin
J
Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications.
Eur J Haematol.
52
1994
134
139
213
Najean
Y
Rain
JD
Dresch
C
et al. 
Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The “French Cooperative Group for the Study of Polycythaemias.”
Leuk Lymphoma.
22(suppl 1)
1996
111
119
214
Nand
S
Messmore
H
Fisher
SG
et al. 
Leukemic transformation in polycythemia vera: analysis of risk factors.
Am J Hematol.
34
1990
32
36
215
Landaw
S
Acute leukemia in polycythemia vera.
Semin Hematol.
13
1976
33
48
216
Castleman
B
Scully
RE
McNeely
BU
Case records of the Massachusetts General Hospital.
N Engl J Med.
288
1973
1343
1350
217
Rosenthal
DS
Moloney
WC
Occurence of acute leukaemia in myeloproliferative disorders.
Br J Hematol.
36
1977
373
382
218
Landaw
SA
Acute leukemia in polycythemia vera.
Semin Hematol.
23
1986
156
165
219
Conrad
ME
Rapport
H
Crosby
WH
Chronic granulocytic leukemia in the aged.
Arch Intern Med.
116
1965
765
775
220
Neu
LT
Shuman
MA
Brown
EB
Polycythemia vera and acute leukemia.
Ann Intern Med.
83
1975
672
673
221
Leone
G
Mele
L
Pulsoni
A
Equitani
F
Pagano
L
The incidence of secondary leukemias.
Haematologica.
84
1999
937
945
222
Henry-Amar
M
Dietrich
PY
Acute leukemia after the treatment of Hodgkin's disease.
Hematol Oncol Clin North Am.
7
1993
369
387
223
Barosi
G
Ambrosetti
A
Centra
A
et al. 
Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia.
Blood.
91
1998
3630
3636
224
Tura
S
Fiacchini
M
Zinzani
PL
Brusamolino
E
Gobbi
PG
Splenectomy and the increasing risk of secondary acute leukemia in Hodgkin's disease.
J Clin Oncol.
11
1993
925
930
225
Socie
G
Henry-Amar
M
Bacigalupo
A
et al. 
Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party.
N Engl J Med.
329
1993
1152
1157
226
Raz
I
Shinar
E
Polliack
A
Pancytopenia with hypercellular bone marrow—a possible paraneoplastic syndrome in carcinoma of the lung: a report of three cases.
Am J Hematol.
16
1984
403
408
227
DeMent
SH
Eggleston
JC
Spivak
JL
Association between mediastinal germ cell tumors and hematologic malignancies: report of two cases and review of the literature.
Am J Surg Pathol.
9
1985
23
30
228
Kaito
K
Kobayashi
M
Katayama
T
et al. 
Long-term administration of G-CSF for aplastic anaemia is closely related to the early evolution of monosomy 7 MDS in adults.
Br J Haematol.
103
1998
297
303
229
Lundberg
WB
Farber
LR
Cadman
EC
Skeel
RT
Spontaneous acute leukemia in polycythemia vera.
Ann Intern Med.
84
1976
294
295
230
Hazani
A
Tatarsky
I
Barzilai
D
Prolonged remission of leukemia associated with polycythemia vera.
Cancer.
40
1977
1297
1299
231
Tefferi
A
Mesa
RA
Nagorney
DM
Schroeder
G
Silverstein
MN
Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients.
Blood.
95
2000
2226
2233
232
Robertson
LE
Pugh
W
O'Brien
S
et al. 
Richter's syndrome:a report on 39 patients.
J Clin Oncol.
11
1993
1985
1989
233
McDonnell
JM
Beschorner
WE
Staal
SP
Spivak
JL
Mann
RB
Richter's syndrome with two different B-cell clones.
Cancer.
58
1986
2031
2037
234
Hirsch
EF
Generalized osteosclerosis with chronic polycythemia vera.
Arch Pathol.
19
1935
91
97
235
Tinney
WS
Hematologic complications of polycythemia vera.
Proc Staff Meetings Mayo Clin.
18
1943
227
231
236
Tinney
WS
Hall
BE
Giffin
HZ
The prognosis of polycythemia vera.
Proc Staff Meetings Mayo Clin.
20
1945
227
230
237
Osgood
EE
Polycythemia vera: age relationships and survival.
Blood.
26
1965
243
256
238
Wasserman
L
The treatment of polycythemia: a panel discussion.
Blood.
32
1968
483
499
239
Videbaek
A
Polycythemia vera: course and prognosis.
Acta Med Scand.
138
1950
179
187
240
Berger
R
Hillion
J
Janvier
D
Chen
Z
Bussel
A
t(8;21) prior to acute leukemia.
Cancer Genet Cytogenet.
70
1993
125
126
241
Valla
D
Casadevall
N
Lacombe
C
et al. 
Primary myeloproliferative disorder and hepatic vein thrombosis: a prospective study of erythroid colony formation in vitro in 20 patients with Budd-Chiari syndrome.
Ann Intern Med.
103
1985
329
334
242
Davis
RB
Acute thrombotic complications of myeloproliferative disorders in young adults.
Am J Clin Pathol.
84
1985
180
185
243
Berk
PD
Goldberg
JD
Donovan
PB
et al. 
Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols.
Semin Hematol.
23
1986
132
143
244
Gruppo Italiano Studio Policitemia
Polycythemia vera: the natural history of 1213 patients followed for 20 years.
Ann Intern Med.
123
1995
656
664
245
Berlin
NI
Treatment of the myeloproliferative disorders with 32P.
Eur J Haematol.
65
2000
1
7
246
Stroebel
CF
Hall
BE
Pease
GL
Evaluation of radiophosphorus therapy in primary polycythemia.
JAMA.
146
1951
1301
1307
247
Verel
D
The treatment of polycythaemia rubra vera with single doses of radioactive phosphorus.
Q J Med.
105
1958
27
43
248
Wasserman
LR
The treatment of polycythemia vera.
Semin Hematol.
13
1976
57
78
249
Anger
BR
Seifried
E
Scheppach
J
Heimpel
H
Budd-Chiari syndrome and thrombosis of other abdominal vessels in the chronic myeloproliferative diseases.
Klin Wochenschr.
67
1989
818
825
250
Rozman
C
Giralt
M
Feliu
E
Rubio
D
Cortes
MT
Life expectancy of patients with chronic nonleukemic myeloproliferative disorders.
Cancer.
67
1991
2658
2663
251
Silverstein
MN
Lainer
AP
Polycythemia vera, 1935-1969.
Mayo Clin Proc.
46
1971
751
753
252
Zankovich
R
Thiele
J
Fiessler
W-D
Fischer
R
Diehl
V
Prognostic parameters in polycythemia vera rubra.
Med Klin.
82
1987
889
894
253
Barabas
AP
Offen
DN
Meinhard
EA
The arterial complications of polycythaemia vera.
Br J Surg.
50
1973
183
187
254
Wasserman
LR
Balcerzak
SP
Berk
PD
et al. 
Influence of therapy on causes of death in polycythemia vera.
Trans Assoc Am Physicians.
94
1981
30
38
255
Schwarcz
TH
Hogan
LA
Endean
ED
et al. 
Thromboembolic complications of polycythemia: polycythemia vera versus smokers' polycythemia.
J Vasc Surg.
17
1993
518
522
256
Parker
RG
Occlusion of the hepatic veins in man.
Medicine.
38
1959
369
402
257
Wasserman
L
Gilbert
HS
Complications of polycythemia vera.
Semin Hematol.
3
1966
199
208
258
Gruppo Italiano Studio Policitemia (GISP)
Low-dose aspirin in polycythaemia vera: a pilot study.
Br J Haematol.
97
1997
453
456
259
Wells
RE
Merrill
EW
Influence of flow properties of blood upon viscosity-hematocrit relationship.
J Clin Invest.
41
1962
1591
1598
260
Replogle
RL
Kundler
H
Gross
RE
Studies on the hemodynamic importance of blood viscosity.
J Thorac Cardiovasc Surg.
50
1965
658
668
261
Begg
TB
Hearns
JB
Components in blood viscosity: the relative contribution of haematocrit, plasma fibrinogen and other proteins.
Clin Sci.
31
1966
87
93
262
Weber
FP
Polycythaemia, erythrocytosis and erythraemia.
Q J Med.
2
1908
85
134
263
Brown
G
Giffin
HZ
Studies of capillaries and blood volume in polycythemia vera.
Am J Med Sci.
166
1923
489
502
264
Cobb
LA
Kramer
RJ
Finch
CA
Circulatory effects of chronic hypervolemia in polycythemia vera.
J Clin Invest.
39
1960
1722
1728
265
Altschule
MD
Volk
MC
Henstell
H
Cardiac and respiratory function at rest in patients with uncomplicated polycythemia vera.
Am J Med Sci.
200
1940
478
483
266
Wanless
IR
Peterson
P
Das
A
et al. 
Hepatic vascular disease and portal hypertension in polycythemia vera and agnogenic myeloid metaplasia: a clinicopathological study of 145 patients examined at autopsy.
Hepatology.
12
1990
1166
1174
267
Thomas
DJ
du Boulay
GH
Marshall
J
et al. 
Cerebral blood-flow in polycythaemia.
Lancet.
2
1977
161
163
268
Fiermonte
G
Aloe Spiriti
MA
Latagliata
R
Petti
MC
Giacomini
P
Polycythaemia vera and cerebral blood flow: a preliminary study with transcranial doppler.
J Intern Med.
234
1993
599
602
269
York
EL
Jones
RL
Menon
D
Sproule
BJ
Effects of secondary polycythemia on cerebral blood flow in chronic obstructive pulmonary disease.
Am Rev Respir Dis.
121
1980
813
818
270
Brown
MM
Wade
JP
Marshall
J
Fundamental importance of arterial oxygen content in the regulation of cerebral blood flow in man.
Brain.
108
pt 1
1985
81
93
271
Wade
JP
Transport of oxygen to the brain in patients with elevated haematocrit values before and after venesection.
Brain.
106
pt 2
1983
513
523
272
Brown
MM
Marshall
J
Regulation of cerebral blood flow in response to changes in blood viscosity.
Lancet.
1
1985
604
609
273
Wade
JP
du Boulay
GH
Marshall
J
et al. 
Cerebral blood flow, haematocrit and viscosity in subjects with a high oxygen affinity haemoglobin variant.
Acta Neurol Scand.
61
1980
210
215
274
Murray
JF
Escobar
E
Circulatory effects of blood viscosity: comparison of methemoglobinemia and anemia.
J Appl Physiol.
25
1968
594
599
275
Massik
J
Tang
YL
Hudak
ML
et al. 
Effect of hematocrit on cerebral blood flow with induced polycythemia.
J Appl Physiol.
62
1987
1090
1096
276
Chien
S
Usami
S
Taylor
HM
Lundberg
JL
Gregersen
MI
Effects of hematocrit and plasma proteins on human blood rheology at low shear rates.
J Appl Physiol.
21
1966
81
87
277
Turitto
V
Weiss
H
Red blood cells: their dual role in thrombus formation.
Science.
207
1976
541
543
278
Vaziri
ND
Mechanism of erythropoietin-induced hypertension.
Am J Kidney Dis.
33
1999
821
828
279
Calabresi
P
Meyer
OO
Polycythemia vera I: clinical and laboratory manifestations.
Ann Intern Med.
50
1958
1182
1216
280
Dintenfass
L
Viscosity of the packed red and white blood cells.
Exp Mol Pathol.
4
1965
597
605
281
Kaplar
M
Kappelmayer
J
Kiss
A
Szabo
K
Udvardy
M
Increased leukocyte-platelet adhesion in chronic myeloproliferative disorders with high platelet counts.
Platelets.
11
2000
183
184
282
Kornberg
A
Rahimi-Levene
N
Yona
R
Mor
A
Rachmilewitz
EA
Enhanced generation of monocyte tissue factor and increased plasma prothrombin fragment1+2 levels in patients with polycythemia vera: mechanism of activation of blood coagulation.
Am J Hematol.
56
1997
5
11
283
Falanga
A
Marchetti
M
Evangelista
V
et al. 
Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera.
Blood.
96
2000
4261
4266
284
Posan
E
Ujj
G
Kiss
A
et al. 
Reduced in vitro clot lysis and release of more active platelet PAI-1 in polycythemia vera and essential thrombocythemia.
Thromb Res.
90
1998
51
56
285
Jensen
MK
de Nully
BP
Lund
BV
Nielsen
OJ
Hasselbalch
HC
Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders.
Br J Haematol.
110
2000
116
124
286
Balduini
CL
Bertolino
G
Noris
P
Piletta
GC
Platelet aggregation in platelet-rich plasma and whole blood in 120 patients with myeloproliferative disorders.
Am J Clin Pathol.
95
1991
82
86
287
Murphy
S
Davis
JL
Walsh
PN
Gardner
FH
Template bleeding time and clinical hemorrhage in myeloproliferative disease.
Arch Intern Med.
138
1978
1251
1253
288
Lamparter
S
Schuermann
M
Heidtmann
H-H
APC resistance as an additional thrombotic risk factor in a patient suffering from polycythemia vera and recurrent thrombosis.
Ann Hematol.
74
1997
49
50
289
Gisslinger
H
Rodeghiero
F
Ruggeri
M
et al. 
Homocysteine levels in polycythaemia vera and essential thrombocythaemia.
Br J Haematol.
105
1999
551
555
290
Wiseman
B
Rohn
R
Bouroncle
B
Myers
W
The treatment of polycythemia vera with radioactive phosporus.
Ann Intern Med.
34
1951
311
330
291
Barach
A
McAlpin
K
Negative results of oxygen therapy in polycythemia vera.
Am J Med Sci.
185
1937
178
181
292
Bomchil
G
Carmena
A
Segade
A
Cavagnaro
F
De Testa
N
Studies on the response to hypoxia and relative hyperoxia in two polycythemia vera patients.
Ind J Med Res.
55
1967
543
548
293
Kaboth
U
Rumpf
KW
Lipp
T
et al. 
Treatment of polycythemia vera by isovolemic large-volume erythrocytapheresis.
Klin Wochenschr.
68
1990
18
25
294
Kutti
J
Weinfeld
A
Platelet survival in active polycythaemia vera with reference to the haematocrit level: an experimental study before and after phlebotomy.
Scand J Haematol.
8
1971
405
414
295
Shaw
D
Tudhope
GR
Thrombocytosis, thrombocythaemia and iron deficiency in patients with polycythaemia vera.
Acta Haematol.
62
1979
223
228
296
Challoner
T
Briggs
C
Rampling
MW
Thomas
DJ
A study of the haematological and haemorheological consequences of venesection.
Br J Haematol.
62
1986
671
678
297
Segel
N
Bishop
JM
Circulatory studies in polycythemia vera at rest and during exercise.
Clin Sci.
32
1967
527
549
298
Boughton
BJ
Chronic myeloproliferative disorders: improved platelet aggregation following venesection.
Br J Hematol.
39
1978
589
598
299
Wehmeier
A
Fricke
S
Scharf
RE
Schneider
W
A prospective study of haemostatic parameters in relation to the clinical course of myeloproliferative disorders.
Eur J Haematol.
45
1990
191
197
300
Boughton
BJ
Dallinger
KJ
125I fibrinogen turnover in polycythaemia: the effect of phlebotomy.
Br J Haematol.
53
1983
97
102
301
Jackson
DP
Hemorrhagic diathesis in patients with cyanotic congenital heart disease: preoperative management.
Ann N Y Acad Sci.
115
1964
235
251
302
Humphrey
PR
Michael
J
Pearson
TC
Red cell mass, plasma volume and blood volume before and after venesection in relative polycythaemia.
Br J Haematol.
46
1980
435
438
303
van Beaumont
W
Greenleaf
JE
Juhos
L
Disproportional changes in hematocrit, plasma volume, and proteins during exercise and bed rest.
J Appl Physiol.
33
1972
55
61
304
Rakita
L
Gillespie
DG
Sancetta
SM
The acute and chronic effects of phlebotomy on general hemodynamics and pulmonary functions of patients with secondary polycythemia associated with pulmonary emphysema.
Am Heart J.
70
1965
466
475
305
Wallis
PJ
Skehan
JD
Newland
AC
et al. 
Effects of erythrapheresis on pulmonary haemodynamics and oxygen transport in patients with secondary polycythaemia and cor pulmonale.
Clin Sci.
70
1986
91
98
306
Rosenthal
A
Nathan
DG
Marty
AT
et al. 
Acute hemodynamic effects of red cell volume reduction in polycythemia of cyanotic congenital heart disease.
Circulation.
42
1970
297
307
307
Weisse
AB
Moschos
CB
Frank
MJ
et al. 
Hemodynamic effects of staged hematocrit reduction in patients with stable cor pulmonale and severely elevated hematocrit levels.
Am J Med.
58
1975
92
98
308
Milligan
DW
MacNamee
R
Roberts
BE
Davies
JA
The influence of iron-deficient indices on whole blood viscosity in polycythaemia.
Br J Haematol.
50
1982
467
471
309
Hutton
RD
The effect of iron deficiency on whole blood viscosity in polycythaemic patients.
Br J Haematol.
43
1979
191
199
310
Rector
WG
Fortuin
NJ
Conley
CL
Non-hematologic effects of chronic iron deficiency: a study of patients with polycythemia vera treated solely with venesections.
Medicine.
61
1982
382
389
311
Moore
DF
Sears
DA
Pica, iron deficiency, and the medical history.
Am J Med.
97
1994
390
393
312
Pearson
TC
Grimes
AJ
Slater
NG
Wetherley-Mein
G
Viscosity and iron deficiency in treated polycythaemia.
Br J Haematol.
49
1981
123
127
313
Birgegard
G
Carlsson
M
Sandhagen
B
Mannting
F
Does iron deficiency in treated polycythemia vera affect whole blood viscosity?
Acta Med Scand.
216
1984
165
169
314
Yip
R
Mohandas
N
Clark
MR
et al. 
Red cell membrane stiffness in iron deficiency.
Blood.
62
1983
99
106
315
Aarts
PA
Bolhuis
PA
Sakariassen
KS
Heethaar
RM
Sixma
JJ
Red blood cell size is important for adherence of blood platelets to artery subendothelium.
Blood.
62
1983
214
217
316
Najean
Y
Dresch
C
Rain
JD
The very-long-term course of polycythaemia: a complement to the previously published data of the Polycythaemia Vera Study Group.
Br J Haematol.
86
1994
233
235
317
Hutt
MSR
Polycythaemia with myelosclerosis.
Proc R Soc Med.
43
1950
903
904
318
Najean
Y
Rain
J
Treatment of polycythemia vera: use of 32P alone or in combination with maintenace therapy using hydroxyurea in 461 patients greater than 65 years of age.
Blood.
89
1997
2319
2327
319
Berlin
NI
Lawrence
JH
Gartland
J
Blood volume in polycythemia as determined by P32 labeled red blood cells.
Am J Med.
9
1950
747
751
320
Murray
JF
Gold
P
Johnson
BL
The circulatory effects of hematocrit variations in normovolemic and hypervolemic dogs.
J Clin Invest.
42
1963
1150
1159
321
Pearson
TC
Botterill
CA
Glass
UH
Wetherley-Mein
G
Interpretation of measured red cell mass and plasma volume in males with elevated venous PCV values.
Scand J Haematol.
33
1984
68
74
322
Pearson
TC
Weatherly-Mein
G
Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia.
Lancet.
2
1978
1219
1221
323
De Stefano
V
Teofili
L
Leone
G
Michiels
JJ
Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis.
Semin Thromb Hemost.
23
1997
411
418
324
Reid
CD
Chanarin
I
Lewis
J
Formes frustes in myeloproliferative disorders: identification by the growth of an endogenous erythroid clone in vitro in patients with arterial vascular disease.
Lancet.
1
1982
14
15
325
Finch
S
Haskins
D
Finch
CA
Iron metabolism hematopoiesis following phlebotomy iron as a limiting factor.
J Clin Invest.
29
1950
1078
1086
326
Reid
J
Hemorrhagic thrombocythemia.
Lancet.
1
1940
584
587
327
Gunz
F
Hemorrhagic thrombocythemia: a critical review.
Blood.
15
1960
706
722
328
Ozer
F
Truax
W
Miesch
D
Levin
W
Primary hemorrhagic thrombocythemia.
Am J Med.
28
1960
807
823
329
Tartaglia
AP
Goldberg
JD
Berk
PD
Wasserman
LR
Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera.
Semin Hematol.
23
1986
172
176
330
Kessler
CM
Klein
HG
Havlik
RJ
Uncontrolled thrombocytosis in chronic myeloproliferative disorders.
Br J Haematol.
50
1982
157
167
331
Wehmeier
A
Daum
I
Jamin
H
Schneider
W
Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders: a retrospective analysis of 260 patients.
Ann Hematol.
63
1991
101
106
332
Berger
S
Aledort
LM
Gilbert
HS
Hanson
JP
Wasserman
LR
Abnormalities of platelet function in patients with polycythemia vera.
Cancer Res.
33
1973
2683
2687
333
Randi
ML
Casonato
A
Fabris
F
Vio
C
Girolami
A
The significance of thrombocytosis in old age.
Acta Haematol.
78
1987
41
44
334
Williams
EC
Shahidi
NT
Benign familial thrombocytosis.
Am J Hematol.
37
1991
124
125
335
Schlemper
RJ
van der Maas
AP
Eikenboom
JC
Familial essential thrombocythemia: clinical characteristics of 11 cases in one family.
Ann Hematol.
68
1994
153
158
336
Eyster
ME
Saletan
SL
Rabellino
EM
et al. 
Familial essential thrombocythemia.
Am J Med.
80
1986
497
502
337
Cohen
N
Almoznino-Sarafian
D
Weissgarten
J
et al. 
Benign familial microcytic thrombocytosis with autosomal dominant transmission.
Clin Genet.
52
1997
47
50
338
Kondo
T
Okabe
M
Sanada
M
et al. 
Familial essential thrombocythemia associated with one-base deletion in the 5′-untranslated region of the thrombopoietin gene.
Blood.
92
1998
1091
1096
339
Buss
DH
Cashell
AW
O'Connor
ML
Richards
F
Case
LD
Occurrence, etiology, and clinical significance of extreme thrombocytosis: a study of 280 cases.
Am J Med.
96
1994
247
253
340
Ruggeri
M
Finazzi
G
Tosetto
A
et al. 
No treatment for low-risk thrombocythaemia: results from a prospective study.
Br J Haematol.
103
1998
772
777
341
Arboix
A
Besses
C
Acin
P
et al. 
Ischemic stroke as first manifestation of essential thrombocythemia.
Stroke.
26
1995
1463
1466
342
Virmani
R
Popovsky
MA
Roberts
WC
Thrombocytosis, coronary artery thrombosis and acute myocardial infarction.
Am J Med.
67
1979
498
506
343
Johnson
M
Gernsheimer
T
Johansen
K
Essential thrombocytosis: underemphasized cause of large-vessel thrombosis.
J Vasc Surg.
22
1995
443
449
344
Harrison
CN
MacHin
SJ
Antiphospholipid antibodies and essential thrombocythemia.
Am J Med.
102
1997
317
318
345
Besses
C
Cervantes
F
Pereira
A
et al. 
Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients.
Leukemia.
13
1999
150
154
346
Watson
KV
Key
N
Vascular complications of essential thrombocythaemia: a link to cardiovascular risk factors.
Br J Haematol.
83
1993
198
203
347
Bellucci
S
Janvier
M
Tobelem
G
et al. 
Essential thrombocythemia: clinical evolutionary and biological data.
Cancer.
58
1986
2440
2447
348
Fenaux
P
Simon
M
Caulier
MT
et al. 
Clinical course of essential thrombocythemia in 147 cases.
Cancer.
66
1990
549
556
349
Budde
U
Scharf
RE
Franke
P
et al. 
Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma.
Blood.
82
1993
1749
1757
350
van Genderen
PJ
Budde
U
Michiels
JJ
van Strik
R
van Vliet
HH
The reduction of large von Willebrand factor multimers in plasma in essential thrombocythaemia is related to the platelet count.
Br J Haematol.
93
1996
962
965
351
van Genderen
PJ
Prins
FJ
Lucas
IS
et al. 
Decreased half-life time of plasma von Willebrand factor collagen binding activity in essential thrombocythaemia: normalization after cytoreduction of the increased platelet count.
Br J Haematol.
99
1997
832
836
352
Edwards
E
Cooley
MH
Peripheral vascular symptoms as the initial manifestation of polycythemia vera.
JAMA.
214
1970
1463
1467
353
Michiels
JJ
Erythromelalgia and vascular complications in polycythemia vera.
Semin Thromb Hemost.
23
1997
441
454
354
Michiels
JJ
Koudstaal
PJ
Mulder
AH
van Vliet
HH
Transient neurologic and ocular manifestations in primary thrombocythemia.
Neurology.
43
1993
1107
1110
355
Hussain
S
Schwartz
JM
Friedman
SA
Chua
SN
Arterial thrombosis in essential thrombocythemia.
Am Heart J.
96
1978
31
36
356
Landolfi
R
Ciabattoni
G
Patrignani
P
et al. 
Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo.
Blood.
80
1992
1965
1971
357
van Genderen
PJ
Michiels
JJ
van Strik
R
Lindemans
J
van Vliet
HH
Platelet consumption in thrombocythemia complicated by erythromelalgia: reversal by aspirin.
Thromb Haemost.
73
1995
210
214
358
Rinder
HM
Schuster
JE
Rinder
CS
et al. 
Correlation of thrombosis with increased platelet turnover in thrombocytosis.
Blood.
91
1998
1288
1294
359
Abdel-Naser
MB
Gollnick
H
Orfanos
CE
Aquagenic pruritis as a presenting symptom of polycythemia vera.
Dermatology.
187
1993
130
133
360
Prentice
TC
Berlin
NI
Lawrence
JH
Effect of therapy on blood volume, blood pressure, and spleen size in polycythemai vera.
Arch Intern Med.
89
1952
584
590
361
Kurzrock
R
Cohen
PR
Erythromelalgia and myeloproliferative disorders.
Arch Intern Med.
149
1989
105
109
362
Anagrelide Study Group
Anagrelide, a therapy for thrombocythemic states: experience in 577 patients.
Am J Med.
92
1992
69
76
363
Silver
RT
Interferon alfa: effects of long-term treatment for polycythemia vera.
Semin Hematol.
34
1997
40
50
364
Silver
RT
Woolf
SH
Hehlmann
R
et al. 
An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology.
Blood.
94
1999
1517
1536
365
Valentine
AD
Meyers
CA
Kling
MA
Richelson
E
Hauser
P
Mood and cognitive side effects of interferon-alpha therapy.
Semin Oncol.
1
1998
39
47
366
Sterkers
Y
Preudhomme
C
Lai
JL
et al. 
Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion.
Blood.
91
1998
616
622
367
Gaston
M
Rosse
WF
The cooperative study of sickle cell disease: review of study design and objectives.
Am J Pediatr Hematol Oncol.
4
1982
197
201
368
Conley
CL
Polycythemia vera: diagnosis and treatment.
Hosp Prac.
22
1987
181
210
369
Handin
RI
Lux
SE
Stossel
TP
Blood: Principles and Practices of Hematology
2nd ed.
2002
Lippincott, Williams, and Wilkins
Philadelphia, PA

Author notes

Jerry L. Spivak, Traylor 924, Johns Hopkins University School of Medicine, 720 Rutland Ave, Baltimore, MD 21205; e-mail: jlspivak@jhmi.edu.